Method and apparatus for pacing during revascularization

Abstract
A system for use during revascularization includes a catheter having an adjustable balloon for delivery a stent, one or more pacing electrodes for delivering one or more pacing pulses to a patient's heart, and a pacemaker configured to generate the one or more pacing pulses to be delivered to the heart via the one or more pacing electrodes. The one or more pacing pulses are delivered at a rate substantially higher than the patient's intrinsic heart rate without being synchronized to the patient's intrinsic cardiac contractions, and are delivered before, during, or after an ischemic event to prevent or reduce cardiac injury.
Description
TECHNICAL FIELD

This document relates generally to cardiac pacing systems and particularly to a system for delivering pacing pulses during a revascularization procedure.


BACKGROUND

The heart is the center of a person's circulatory system. It includes an electro-mechanical system performing two major pumping functions. The left portions of the heart draw oxygenated blood from the lungs and pump it to the organs of the body to provide the organs with their metabolic needs for oxygen. The right portions of the heart draw deoxygenated blood from the body organs and pump it to the lungs where the blood gets oxygenated. These pumping functions are resulted from contractions of the myocardium (cardiac muscles). In a normal heart, the sinoatrial node, the heart's natural pacemaker, generates electrical impulses, called action potentials, that propagate through an electrical conduction system to various regions of the heart to excite the myocardial tissues of these regions. Coordinated delays in the propagations of the action potentials in a normal electrical conduction system cause the various portions of the heart to contract in synchrony to result in efficient pumping functions. A blocked or otherwise abnormal electrical conduction and/or deteriorated myocardial tissue cause dyssynchronous contraction of the heart, resulting in poor hemodynamic performance, including a diminished blood supply to the heart and the rest of the body. The condition where the heart fails to pump enough blood to meet the body's metabolic needs is known as heart failure.


Myocardial infarction (MI) is the necrosis of portions of the myocardial tissue resulted from cardiac ischemia, a condition in which the myocardium is deprived of adequate oxygen and metabolite removal due to an interruption in blood supply caused by an occlusion of a blood vessel such as a coronary artery. The necrotic tissue, known as infarcted tissue, loses the contractile properties of the normal, healthy myocardial tissue. Consequently, the overall contractility of the myocardium is weakened, resulting in an impaired hemodynamic performance. Following an MI, cardiac remodeling starts with expansion of the region of infarcted tissue and progresses to a chronic, global expansion in the size and change in the shape of the entire left ventricle. The consequences include a further impaired hemodynamic performance and a significantly increased risk of developing heart failure.


When a blood vessel such as the coronary artery is partially or completely occluded, a revascularization procedure such as percutaneous transluminal coronary angioplasty (PCTA) can be performed to reopen the occluded blood vessel. However, the revascularization procedure itself involves a temporary occlusion of the coronary artery. In addition, plaques dislodged and displaced by the revascularization procedure may enter small blood vessels branching from the blood vessel in which the revascularization is performed, causing occlusion of these small blood vessels. This complication is referred to as “snow plow effect.” The revascularization procedure may also cause distal embolization, i.e., obstruction of the artery caused by the plaque dislodged during the procedure. The temporary occlusion, snow plow effect, and distal embolization may each cause cardiac injuries such as further expansion of the region of infarcted tissue. In addition, the revascularization procedure is known to increase the risk for occurrences of arrhythmia.


Therefore, there is a need for minimizing cardiac injury and preventing arrhythmias during the revascularization procedure.


SUMMARY

A system for use during revascularization includes a catheter having an adjustable balloon for delivery a stent and a pacemaker to deliver one or more pacing pulses to a patient's heart to prevent or reduce cardiac injury associated with the revascularization procedure. In one embodiment, a system includes a catheter, one or more pacing electrodes, and a pacemaker. The catheter includes a proximal end portion, a distal end portion, and an elongate body extending therebetween. The distal end portion includes an adjustable balloon for delivering a stent. The one or more pacing electrodes configured to deliver one or more pacing pulses to a heart of a patient. The pacemaker is configured to generate the one or more pacing pulses to be delivered to the heart via the one or more pacing electrodes. The one or more pacing pulses are delivered at a rate substantially higher than the patient's intrinsic heart rate without being synchronized to the patient's intrinsic cardiac contractions, and are delivered before, during, or after an ischemic event to prevent or reduce cardiac injury.


In one embodiment, a method for delivering cardiac pacing to a patient is provided. A stent is delivered using a catheter including a stent delivery system causing an ischemic event in a patient. The heart of the patient is paced before, during, or after the ischemic event in a manner such that the pacing pulses are delivered at a rate substantially higher than the patient's intrinsic heart rate without being synchronized to the patient's intrinsic cardiac contractions.


This Summary is an overview of some of the teachings of the present application and not intended to be an exclusive or exhaustive treatment of the present subject matter. Further details about the present subject matter are found in the detailed description and appended claims. Other aspects of the invention will be apparent to persons skilled in the art upon reading and understanding the following detailed description and viewing the drawings that form a part thereof. The scope of the present invention is defined by the appended claims and their legal equivalents.





BRIEF DESCRIPTION OF THE DRAWINGS

The drawings illustrate generally, by way of example, various embodiments discussed in the present document. The drawings are for illustrative purposes only and may not be to scale.



FIG. 1 is an illustration of an embodiment of a system providing for pacing during revascularization and portions of an environment in which the system is used.



FIG. 2 is an illustration of an embodiment of a pacemaker providing for pacing during revascularization.



FIG. 3 is a timing diagram illustrating an exemplary embodiment of a cardiac protection pacing sequence for the pacing during revascularization.



FIG. 4 is an illustration of an embodiment of a PTVI device with pacing electrodes.



FIG. 5 is an illustration of another embodiment of a PTVI device with pacing electrodes.



FIG. 6 is an illustration of another embodiment of a PTVI device with pacing electrodes.



FIG. 7 is an illustration of an exemplary specific embodiment of the distal end portion of a PTVI device with pacing electrode(s).



FIG. 8 is an illustration of another exemplary specific embodiment of the distal end portion of a PTVI device with pacing electrode(s).



FIG. 9 is an illustration of another exemplary specific embodiment of the distal end portion of a PTVI device with pacing electrode(s).



FIG. 10 is an illustration of another exemplary specific embodiment of the distal end portion of a PTVI device with pacing electrode(s).



FIG. 11 is an illustration of another exemplary specific embodiment of the distal end portion of a PTVI device with pacing electrode(s).



FIG. 12 is an illustration of another exemplary specific embodiment of the distal end portion of a PTVI device with pacing electrode(s).



FIG. 13 is an illustration of another exemplary specific embodiment of the distal end portion of a PTVI device with pacing electrode(s).





DETAILED DESCRIPTION

In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that the embodiments may be combined, or that other embodiments may be utilized and that structural, logical and electrical changes may be made without departing from the spirit and scope of the present invention. The following detailed description provides examples, and the scope of the present invention is defined by the appended claims and their legal equivalents.


It should be noted that references to “an”, “one”, or “various” embodiments in this disclosure are not necessarily to the same embodiment, and such references contemplate more than one embodiment.


This document discusses a pacing system for minimizing damage to the myocardial tissue and preventing arrhythmias during a revascularization procedure that requires temporary occlusion of one or more blood vessels. In a specific application, this system provides for cardiac protection pacing during a percutaneous transluminal coronary angioplasty (PTCA) procedure. Cardiac protection pacing includes the delivery of a pacing therapy before, during, and/or after the temporary occlusion of a coronary artery associated with the PTCA procedure, for preventing or reducing adverse effects of the occlusion, which is an ischemic event. The pacing therapy can be delivered at almost any time during a revascularization procedure, as soon as pacing electrodes are in place, without substantially interfering with the revascularization procedure.


To deliver pacing pulses during a revascularization procedure, one or more pacing electrodes are incorporated onto the distal end portion of a PTVI device. Examples of such PTVI device include guide wires, dilatation balloon catheters, stent delivery systems, brachytherapy devices, atherectomy devices, distal embolization protection devices, and guiding catheters. A pacemaker is connected to the proximal end portion of the PTVI device to deliver the pacing pulses to the heart through the one or more electrodes. In one embodiment, the pacemaker is an external pacing device such as a pacing system analyzer. This approach to cardiac protection pacing allows delivery of pacing pulses as soon as the PTVI device is inserted.



FIG. 1 is an illustration of an embodiment of a system 100 providing for pacing during revascularization and portions of an environment in which system 100 is used. System 100 includes a PTVI device 110, a pacemaker 130, and a cable 125 connecting PTVI device 110 and pacemaker 130. When needed, system 100 also includes a reference electrode 122, which is a surface electrode, such as a skin patch electrode, connected to a lead 120. Lead 120 is connected to a connector 118 allowing its connection to cable 125.


PTVI device 110 is used during a revascularization procedure and includes a distal end portion 111 for intravascular placement and a proximal end portion 112. Proximal end portion 112 includes a proximal end device 114 and pacing connectors 116 and 117. Proximal end device 114 includes various connectors and other structures allowing manipulation of PTVI device 110 including the percutaneous transluminal insertion of the device and operation of an angioplasty device at distal end 111. Pacing connectors 116 and 117 provide for electrical connections between cable 125 and PTVI device 110. In one embodiment, as illustrated in FIG. 1, PTVI device 110 is a percutaneous transluminal coronary angioplasty (PTCA) device used in a PTCA procedure. During the PTCA procedure, an opening 105 is made on a femoral artery 104 in a patient's body 102. PTVI device 110 is inserted into femoral artery 104 and advanced to an aorta 106 and then to a right coronary artery 107, which is narrowed or blocked. The angioplasty device at distal end 111 is then used to open up the blocked right coronary artery 107. In another embodiment, PTVI device 110 is used to open up a blocked left coronary artery 108.


Distal end portion 111 of PTVI device 110 includes one or more pacing electrodes to allow pacing pulses to be delivered to a heart 101 during the PTCA procedure. In one embodiment, pacing pulses are delivered through two pacing electrodes on distal end portion 111 of PTVI device 110. In another embodiment, pacing pulses are delivered through a pacing electrode on distal end portion 111 of PTVI device 110 and surface electrode 122 functioning as the return electrode for pacing.


Pacemaker 130 delivers pacing pulses by following a cardiac protection pacing sequence. In one embodiment, the cardiac protection pacing sequence provides for cardiac protection pacing following an ischemic event to prevent arrhythmias and cardiac injuries caused by the ischemic event. In one embodiment, pacemaker 130 is an external pacemaker such as a pacing system analyzer (PSA). In another embodiment, pacemaker 130 includes an implantable pacemaker adapted for external use.


It is to be understood that FIG. 1 is for illustrative, but not restrictive, purposes. For example, the physical structure of proximal end portion 112 depends on functional and ease-of-use considerations. Proximal end device 114 represents a structure that accommodates all the mechanical connection and access requirements, which depend on the specific configuration and function of PTVI device 110. In one embodiment, proximal end device 114 includes an integrated device as illustrated in FIG. 1. In another embodiment, proximal end device 114 branches out into multiple connectors and/or other devices. Pacing connectors 116 and 117 represent a structure that accommodates all the electrical connections required for delivering pacing pulses from pacemaker 130 to PTVI device 110. The number of pacing connectors depends on the number of pacing electrodes incorporated onto PTVI device 110 and how it is to be connected to cable 125. In one embodiment, when more than one electrical connection is incorporated onto PTVI device 110, proximal end portion 112 includes branched-out pacing connectors such as pacing connectors 116 and 117 as illustrated in FIG. 1. In another embodiment, proximal end portion 112 includes a single connector providing for multiple, independent electrical connections.



FIG. 2 is an illustration of an embodiment of a pacemaker 230 that provides for pacing during revascularization. Pacemaker 230 is a specific embodiment of pacemaker 130 and includes a pacing output circuit 232 and a control circuit 234. In one embodiment, pacemaker 230 further includes a user interface to allow a user to control the delivery of the pacing pulses by controlling the pacing parameters and/or the timing of the delivery.


Pacing output circuit 232 delivers pacing pulses to PTVI device 110 through cable 125. Control circuit 234 controls the delivery of the pacing pulses. In one embodiment, as illustrated in FIG. 2, control circuit 234 includes a cardiac protection pacing sequence timer 236, which times a predetermined cardiac protection pacing sequence. The cardiac protection pacing sequence is predetermined to provide cardiac protection pacing before, during, and/or after an ischemic event such as the occlusion of a coronary artery by PTVI device 110 during a PTCA procedure.



FIG. 3 is a timing diagram illustrating an exemplary embodiment of a cardiac protection pacing sequence for pacing during a revascularization procedure such as a PTCA procedure. The cardiac protection pacing sequence is initiated after a time interval 340, which starts when the insertion of PTVI device into body 102 is completed. Time interval 340 expires before, during, and/or after an ischemic event that occurs when the blood vessel at the revascularization site is substantially occluded by PTVI device 110. In one embodiment, the cardiac protection pacing sequence is applied repeatedly, before, during, and/or after the ischemic event, during the revascularization procedure.


In the embodiment illustrated in FIG. 3, the cardiac protection pacing sequence includes alternating pacing and non-pacing periods. Each pacing period is a pacing duration during which the pacing pulses are delivered in a predetermined pacing mode. The non-pacing period is a non-pacing duration during which no pacing pulses is delivered. In one embodiment, during each pacing period, rapid, asynchronous pacing is applied. In other words, pacing pulses are delivered at a rate substantially higher than the patient's intrinsic heart rate without being synchronized to the patient's intrinsic cardiac contractions. For illustrative purpose only, FIG. 3 shows a cardiac protection pacing sequence that includes two cycles of alternating pacing and non-pacing periods: pacing period 342A, non-pacing periods 344A, pacing period 342B, and non-pacing periods 344B. In one embodiment, the number of the cycles of alternating pacing and non-pacing periods is programmable, and each of the pacing and non-pacing periods is programmable. In one embodiment, the cardiac protection pacing sequence is initiated before the ischemic event and includes approximately 1 to 4 cycles of alternating pacing and non-pacing periods. The pacing period is in a range of approximately 30 seconds to 20 minutes. The non-pacing period is in a range of approximately 30 seconds to 20 minutes. In a specific example, the cardiac protection pacing sequence initiated before the ischemic event includes 3 cycles of alternating pacing and non-pacing periods each being approximately 5-minute long. In one embodiment, the cardiac protection pacing sequence is initiated during the ischemic event and includes approximately 1 to 4 cycles of alternating pacing and non-pacing periods. The pacing period is in a range of approximately 30 seconds to 20 minutes. The non-pacing period is in a range of approximately 30 seconds to 20 minutes. In a specific example, the cardiac protection pacing sequence delivered during the ischemic event includes 3 cycles of alternating pacing and non-pacing periods each being approximately 5-minute long. In one embodiment, the cardiac protection pacing sequence is initiated after the ischemic event and includes approximately 1 to 4 cycles of alternating pacing and non-pacing periods. The pacing period is in a range of approximately 10 seconds to one minute. The non-pacing period is in a range of approximately 10 seconds to one minute. In one specific example, the cardiac protection pacing sequence delivered after the ischemic event includes 2 to 4 cycles of alternating pacing and non-pacing periods each being approximately 30-second long.


In various other embodiments, the cardiac protection pacing sequence includes pacing at one or more atrial tracking or other pacing modes. Examples of pacing modes used in such a cardiac protection pacing sequence include VDD, VVI, and DDD modes. In various embodiments, the VVI and DDD modes are delivered with a lower rate limit higher than the patient's intrinsic heart rate. In one embodiment, pacing therapy is delivered to prevent restenosis. In another embodiment, pacing therapy is delivered to treat an arrhythmia during the revascularization procedure, for example, when the patient experiences brady cardia during the procedure.


In one embodiment, the pacing pulses are delivered according to the cardiac protection pacing sequence through PTVI device 110 during the revascularization procedure. After the revascularization procedure, if an implantable pacemaker is implanted into the patient, pacing therapy is delivered to heart 101 through one or more implantable leads from the implantable pacemaker. The pacing therapy includes delivering pacing pulses according to a pacing sequence that is substantially identical or similar to the cardiac protection pacing sequence applied during the revascularization procedure. The pacing sequence is delivered according to a predetermined schedule, such as on a predetermined periodic basis. This prevents or reduces possible cardiac injury after the revascularization, including cardiac injury and occurrences of arrhythmia caused by ischemic events including myocardial infarction that may be experienced by the patient after the implantation of the implantable pacemaker.



FIG. 4 is an illustration of an embodiment of a PTVI device 410. PTVI device 410 is a specific embodiment of PTVI device 110 and has an elongate body 450 between a distal end portion 451 and a proximal end portion 452. Distal end portion 451 is configured for intravascular placement and includes a distal tip 453. Distal tip 453 includes a pacing electrode 454. A conductor 456 extends longitudinally within elongate body 450 and connected between pacing electrode 454 and a connector 458, which is part of proximal end portion 452.


In one embodiment, elongate body 450 is an elongate cylindrical shaft having a diameter in a range of approximately 0.2 mm to 1.5 mm, and PTVI device 410 has a length in a range of approximately 30 cm to 300 cm. In another embodiment, elongate body 450 is an elongate tubular body having an outer diameter in a range of approximately 0.5 mm to 8 mm and an inner diameter (of a lumen) in a range of approximately 0.4 mm to 7 mm. In one embodiment, PTVI device 410 is a guide wire such as a coronary guide wire. PTVI device 410 is formed by conductor 456, which is insulated throughout its length except for pacing electrode 454 and connector 458. As the core of the guide wire, conductor 456 is made of a metallic material such as stainless steel, alloys of nickel, titanium, and cobalt, and is insulated with a material such as silicone, polyurethane, Teflon, and polytetrafluoroethylene (PTFE). Electrode 454 is made of a metallic material such as platinum, and iridium alloy. In another embodiment, conductor 456 is a metal wire other than the core of the guide wire. In another embodiment, PTVI device 410 is a guiding catheter such as a coronary guiding catheter. The coronary guiding catheter includes an elongate tubular body with a lumen extending between distal end portion 452 and proximal end portion 452. In another embodiment, PTVI device 410 includes two or more electrodes in distal end portion 451 and two or more conductors each connected between one of the electrodes and connector 458, which is a multi-conductor connector allowing for two or more electrically insulated connections.



FIG. 5 is an illustration of another embodiment of a PTVI device 510. PTVI device 510 is another specific embodiment of PTVI device 110 and has an elongate body 550 between a distal end portion 551 and a proximal end portion 552. Distal end portion 551 is configured for intravascular placement and includes a distal tip 553 and an angioplasty device 560. Angioplasty device 560 has one end approximately adjacent to distal tip 553 and another end coupled to elongate body 550. In various embodiments, angioplasty device 560 allows for application of an angioplasty therapy such as vascular dilatation, stent delivery, brachytherapy (radiotherapy), atherectomy, or embolic protection. In one embodiment, angioplasty device 560 includes an adjustable portion that has controllable expandability and contractibility. In one specific embodiment, angioplasty device 560 includes a balloon that is inflated and deflated through a passageway longitudinally extending within elongate body 550 and connected between the chamber of the balloon and a connector at proximal end portion 552. The balloon is inflatable using an air pump connected to that connector. In one embodiment, distal tip 553 is a tapered tip that facilitates the insertion of PTVI device 510 into a blood vessel. A pacing electrode 554A is approximately adjacent to one end of angioplasty device 560. Another pacing electrode 554B is approximately adjacent to the other end of angioplasty device 560. A conductor 556A extends longitudinally within elongate body 550 and is connected between pacing electrode 554A and a pacing connector 516, which is part of proximal end portion 552. A conductor 556B extends longitudinally within elongate body 550 and is connected between pacing electrode 554B and a pacing connector 517, which is also part of proximal end portion 552. In an alternative embodiment, pacing connectors 516 and 517 are physically integrated into one multi-conductor connector. Proximal end portion 552 also includes a proximal end device 514. Proximal end device 514 represents a structure that accommodates all the mechanical connection and access requirements, which depend on the function of angioplasty device 560. In one embodiment, proximal end device 514 includes an integrated device as illustrated in FIG. 5. In another embodiment, proximal end device 514 branches out into multiple connectors and/or other devices.


In one embodiment, elongate body 550 is an elongate cylindrical shaft having a diameter in a range of approximately 1 mm to 5 mm. PTVI device 510 has a length in a range of approximately 50 cm to 150 cm. In one embodiment, angioplasty device 560 has a fixed, substantially cylindrical shape with a diameter in a range of approximately 1 mm to 10 mm. In another embodiment, angioplasty device 560 has an adjustable, substantially cylindrical or semi-spherical shape with a maximum diameter in a range of approximately 1 mm to 10 mm when fully expanded and a maximum diameter in a range of approximately 0.5 mm to 5 mm when fully contracted. In one embodiment, PTVI device 510 is a PTCA catheter and includes a lumen longitudinally extending within elongate body 550 to accommodate at least a portion of a guide wire such as PTVI device 410. In one embodiment, conductors 556A and 556B are each made of a metallic material such as stainless steel and alloys of nickel, titanium, and cobalt. Electrodes 554A and 554B are each made of a metallic material such as platinum, and iridium alloy. Elongate body 550 has a tubular outer shell made of a material such as silicone, polyurethane, Teflon, and polytetrafluoroethylene (PTFE).


In one alternative embodiment, PTVI device 510 includes one electrode in distal end portion 551 and one conductor connected between that electrode and a pacing connector in proximal end portion 552. In another alternative embodiment, PTVI device 510 includes three or more electrodes in distal end portion 551 and three or more conductors each connected between one of the electrodes a pacing connector in proximal end portion 552.



FIG. 6 is an illustration of another embodiment of a PTVI device 610 with pacing electrodes. PTVI device 610 is another specific embodiment of PTVI device 110 and is similar to PTVI device 510 except for the location of the pacing electrodes. PTVI device 610 has a distal end portion 651, where pacing electrodes 654A and 654B are attached onto angioplasty device 560. In one specific embodiment, pacing electrodes 654A and 654B are each approximately adjacent to one end of angioplasty device 560.


PTVI devices 410, 510, and 610 are illustrated in FIGS. 4-6 for illustrative but not restrictive purposes. For example, the one or more pacing electrodes can be distributed on the distal portion of a PTVI device in any way allowing proper delivery of pacing pulses. In various embodiments, the one or more pacing electrodes can be distributed on the angioplasty device, the distal tip, and/or the elongate body at the distal end portion of the PTVI device.



FIGS. 7-13 illustrate exemplary specific embodiments of the distal end of a PTVI device with one or more pacing electrodes. In one embodiment, PTVI device 410, 510, and 610 are each made by modifying a selected product of Guidant Corporation's Vascular Intervention division (“Guidant VI,” Temecula, Calif.) to include one or more pacing electrodes. Examples of such a selected product are illustrated in FIGS. 7-13. According to the present subject matter, one or more pacing electrodes are incorporated onto any PTVI device as deemed appropriate by one skilled in the art. Such PTVI devices include, but are not limited to, devices that belong to the same category as those illustrated in FIGS. 7-13.



FIG. 7 is an illustration of an embodiment of the distal end portion 751, which is an exemplary specific embodiment of distal end portion 451. Distal end portion 751 is the distal portion of a coronary guide wire (Guidant VI's HI-TORQUE PILOT™ 50 Guide Wire with Hydrocoat hydrophilic coating) modified to include a pacing electrode 754. The coronary guide wire includes an elongate body 750 being an insulated conductive wire that extends to a distal tip 753. The coronary guide wire has a length of approximately 190 cm or 300 cm, depending on the specific product model, and a diameter of approximately 0.014 inches (0.3556 mm). The conductive wire is connected to pacing electrode 754 at the distal end of distal tip 753. Distal end portion 751 also includes a radiopaque marker 762, which allows for measurement of lesion length. In one embodiment, the single-electrode configuration allows the coronary guide wire to have a relatively small diameter. In one embodiment, pacing pulses are delivered using a unipolar electrode configuration, with a return electrode such as reference electrode 122.



FIG. 8 is an illustration of an embodiment of the distal end portion 851, which is an exemplary specific embodiment of distal end portion 551. Distal end portion 851 is the distal portion of a coronary dilatation balloon catheter (Guidant VI's VOYAGER™ RX Coronary Dilatation Catheter) modified to include pacing electrodes 854A and 854B. Distal end portion 851 is extended from an elongate body 850 and includes a tapered tip 853 and an angioplasty device 860. The coronary dilatation balloon catheter has a usable catheter working length of approximately 143 cm and accommodates a guide wire having a maximum diameter of 0.014 inches (0.3556 mm), such as the coronary guide wire illustrated in FIG. 7, that is used for insertion of the catheter. Elongate body 850 includes a shaft having a diameter in a range of approximately 2.0 to 2.8 French, depending on the specific product model. Angioplasty device 860 is a specific embodiment of angioplasty device 560 and includes an adjustable balloon 864 that is approximately adjacent to tapered tip 853. Adjustable balloon 864 is used for coronary dilatation by inflation. When inflated, adjustable balloon 864 has a diameter in a range of 1.5 mm to 4 mm, depending on the specific product model. Pacing electrode 854A is approximately adjacent to one end of adjustable balloon 864. Pacing electrode 854B is approximately adjacent to the other end of adjustable balloon 864. Pacing pulses are delivered using a bipolar configuration with pacing electrodes 854A and 854B, a unipolar configuration using one of pacing electrodes 854A and 854B and a return electrode such as reference electrode 122, or a combination of bipolar and unipolar configurations.



FIG. 9 is an illustration of an embodiment of the distal end portion 951, which is an exemplary specific embodiment of distal end portion 551. Distal end portion 951 is the distal portion of a stent delivery platform (Guidant VI's GUIDANT MULTI-LINK RX ULTRA™ Coronary Stent System) modified to include pacing electrodes 954A and 954B. Distal end portion 951 is extended from an elongate body 950 and includes a tip 953 and an angioplasty device 960. The stent delivery platform accommodates a guide wire having a maximum diameter of 0.014 inches (0.3556 mm), such as the coronary guide wire illustrated in FIG. 7, that is used for insertion of the device. Angioplasty device 960 is a specific embodiment of angioplasty device 560 and includes an adjustable balloon 964 that is approximately adjacent to tip 953. Adjustable balloon 964 is used for placing a stent in the coronary artery where distal end portion 951 has reached. Depending on the specific product model, the working size of adjustable balloon 964 accommodates stents having a diameter in a range of approximately 3.5 mm to 5 mm and a length in a range of approximately 13 mm to 38 mm. Pacing electrode 954A is approximately adjacent to one end of adjustable balloon 964. Pacing electrode 954B is approximately adjacent to the other end of adjustable balloon 964. Distal end portion 951 also includes a pair of radiopaque markers 962A and 962B on adjustable balloon 964 for indicating the balloon's working length. Pacing pulses are delivered using a bipolar configuration with pacing electrodes 954A and 954B, a unipolar configuration using one of pacing electrodes 954A and 954B and a return electrode such as reference electrode 122, or a combination of bipolar and unipolar configurations.



FIG. 10 is an illustration of an embodiment of the distal end portion 1051, which is an exemplary specific embodiment of distal end portion 551. Distal end portion 1051 is the distal portion of a brachytherapy device (Guidant VI's GALILEO® Intravascular Radiotherapy System) modified to include pacing electrodes 1054A and 1054B. Distal end portion 1051 is extended from an elongate body 1050 and includes a tapered tip 1053 and an angioplasty device 1060. The brachytherapy device accommodates a guide wire having a maximum diameter of 0.014 inches (0.3556 mm), such as the coronary guide wire illustrated in FIG. 7, that is used for insertion of the device. Angioplasty device 1060 is a specific embodiment of angioplasty device 560 and includes an brachytherapy device 1066 that is approximately adjacent to tapered tip 1053 and includes a chamber containing an radiological agent to provide therapeutic doses to the tissue area where distal end portion 1051 has reached. Brachytherapy device 1066 has diameter in a range of approximately 2.5 mm, 3.0 mm, or 3.5 mm and a therapeutic dose length of approximately 32 mm or 52 mm, depending on the specific product model. Pacing electrode 1054A is approximately adjacent to one end of brachytherapy device 1066. Pacing electrode 1054B is approximately adjacent to the other end of brachytherapy device 1066. Distal end portion 1051 also includes a pair of radiopaque markers 1062A and 1062B on brachytherapy device 1066 for indicating the therapeutic dose length. Pacing pulses are delivered using a bipolar configuration with pacing electrodes 1054A and 1054B, a unipolar configuration using one of pacing electrodes 1054A and 1054B and a return electrode such as reference electrode 122, or a combination of bipolar and unipolar configurations.



FIG. 11 is an illustration of an embodiment of the distal end portion 1151, which is an exemplary specific embodiment of distal end portion 551. Distal end portion 1151 is the distal portion of an atherectomy device (Guidant VI's FLEXI-CUT® Directional Debulking System) modified to include pacing electrodes 1154A and 1154B. Distal end portion 1151 is extended from an elongate body 1150 and includes a tapered tip 1153 and an angioplasty device 1160. The atherectomy device has a working length of approximately 134 cm. Angioplasty device 1160, which is a specific embodiment of angioplasty device 560, is an atherectomy device that includes a cylindrical nosecone 1168 that is approximately adjacent to tapered tip 1153 and a cutter 1170 connected to cylindrical nosecone 1168. Cutter 1170 cuts the plaques that block or narrow the portion of the coronary artery where distal end portion 1151 has reached. Cylindrical nosecone 1168 stores the cut plaques. Depending on the specific product model, atherectomy device is capable of operating in blood vessels having diameters ranging from approximately 2.5 mm to 4 mm. Pacing electrode 1154A is on tapered tip 1153 and approximately adjacent to the distal end of cylindrical nosecone 1168. Pacing electrode 1154B is on cutter 1170 and approximately adjacent to the distal end of cutter 1170. Pacing pulses are delivered using a bipolar configuration with pacing electrodes 1154A and 1154B, a unipolar configuration using one of pacing electrodes 1154A and 1154B and a return electrode such as reference electrode 122, or a combination of bipolar and unipolar configurations.



FIG. 12 is an illustration of an embodiment of the distal end portion 1251, which is an exemplary specific embodiment of distal end portion 551. Distal end portion 751 is the distal portion of a distal embolization protection device (Guidant VI's RX ACCUNET™ Embolic Protection System) modified to include pacing electrodes 1254A and 1254B. Distal end portion 1251 is extended from an elongate body 1250 and includes a tip 1253 and an angioplasty device 1260. Elongate body 1250 is based on a coronary guide wire that has a diameter of 0.014 inches (0.3556 mm) and extends throughout substantially the full length of the distal embolization protection device, which is either 190 cm or 300 cm, depending on the specific product model. Angioplasty device 1260, which is a specific embodiment of angioplasty device 560, is an embolic protection device that includes a filter basket 1272 with a filter membrane 1274 to contain and remove embolic material including plaques dislodged during the angioplasty procedure. Filter basket 1272 is flexible, with available basket diameters (when fully expanded) of 4.5 mm, 5.5 mm, 6.5 mm, and 7.5 mm, depending on the specific product model. Pacing electrode 1254A is on tip 1253. Pacing electrode 1254B is on elongate body 1250 and is approximately adjacent to the proximal end of filter basket 1272. Pacing pulses are delivered using a bipolar configuration with pacing electrodes 1254A and 1254B, a unipolar configuration using one of pacing electrodes 1254A and 1254B and a return electrode such as reference electrode 122, or a combination of bipolar and unipolar configurations.



FIG. 13 is an illustration of an embodiment of the distal end portion 1351, which is another exemplary specific embodiment of distal end portion 451. Distal end portion 1351 is the distal portion of a coronary guiding catheter (Guidant VI's VIKING OPTIMAT™ 50 Guiding Catheter) modified to include a pacing electrode 1354. The coronary guiding catheter includes a tubular elongate body 1350 that has a distal tip 1353, and a lumen having a diameter of 6 French (0.068 inches), 7 French (0.078 inches), or 8 French (0.091 inches). In one embodiment, the single-electrode configuration allows the coronary guiding catheter to have a relatively small diameter. In one embodiment, pacing pulses are delivering using a unipolar electrode configuration, with a return electrode such as reference electrode 122.


It is to be understood that the above detailed description, including the various configurations of PT VI devices, is intended to be illustrative, and not restrictive. In general, cardiac protection pacing is applied to prevent or reduce cardiac injury and/or occurrences of arrhythmia caused by an ischemic event by using one or more pacing electrodes incorporated onto any intravascular device and a pacemaker that is capable of delivering pacing pulses according to a predetermined cardiac protection pacing sequence. Other embodiments will be apparent to those of skill in the art upon reading and understanding the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.

Claims
  • 1. A system for use during revascularization procedure, comprising: a percutaneous transluminal vascular intervention (PTVI) device including: a proximal end portion including one or more pacing connectors;a distal end portion configured for intravascular placement, the distal end portion including a tip and an angioplasty device having a first end approximately adjacent to the tip and a second end;an elongate body coupled between the proximal end portion and the second end of the angioplasty device; andone or more pacing electrodes incorporated onto the distal end portion and electrically connected to the one or more pacing connectors; anda pacemaker configured to be connected to the one or more pacing connectors of the PTVI device and deliver pacing pulses to the one or more pacing electrodes.
  • 2. The system of claim 1, wherein the one or more pacing electrodes comprise a first electrode approximately adjacent to the first end of the angioplasty device.
  • 3. The system of claim 2, wherein the one or more pacing electrodes further comprise a second electrode approximately adjacent to the second end of the angioplasty device.
  • 4. The system of claim 1, wherein the one or more pacing electrodes comprise at least one pacing electrode incorporated onto the angioplasty device.
  • 5. The system of claim 1, wherein the one or more pacing electrodes comprise at least one pacing electrode incorporated onto the elongate body.
  • 6. The system of claim 1, wherein the distal end portion further comprises one or more radiopaque markers.
  • 7. The system of claim 1, wherein the angioplasty device comprises an adjustable angioplasty device having controlled expandability and contractibility.
  • 8. The system of claim 7, wherein the adjustable angioplasty device comprises a coronary dilatation balloon configured for coronary dilatation.
  • 9. The system of claim 7, wherein the adjustable angioplasty device comprises a coronary stent delivery balloon configured for coronary stent placement.
  • 10. The system of claim 7, wherein the angioplasty device comprises a distal embolization protection device including an adjustable filter basket adapted to contain and remove embolic material.
  • 11. The system of claim 1, wherein the angioplasty device comprises a brachytherapy device including a chamber containing a radiological agent.
  • 12. The system of claim 1, wherein the angioplasty device comprises an atherectomy device including a cylindrical nosecone coupled to the distal tip and a cutter to the nosecone, the cutter configured to cut tissue, the cylindrical nosecone configured to store cut tissue.
  • 13. A method for providing a system for revascularization, comprising: providing a percutaneous transluminal vascular intervention (PTVI) device including a distal end portion configured for intravascular placement;incorporating one or more pacing electrodes onto the distal end portion of the PTVI device; andproviding a pacemaker configured to be connected to a proximate end of the PTVI device and deliver pacing pulses to the one or more pacing electrodes.
  • 14. The method of claim 13, further comprising: enclosing one or more conductors in an elongate body of the PTVI device; andconnecting each of the one or more conductors to one of the one or more pacing electrodes.
  • 15. The method of claim 14, wherein incorporating the one or more pacing electrodes onto the distal end portion of the PTVI device comprises incorporating the one or more pacing electrodes onto a distal end portion of a coronary guide wire.
  • 16. The method of claim 14, wherein incorporating the one or more pacing electrodes onto the distal end portion of the PTVI device comprises incorporating the one or more pacing electrodes onto a distal end portion of a coronary dilatation balloon catheter.
  • 17. The method of claim 14, wherein incorporating the one or more pacing electrodes onto the distal end portion of the PTVI device comprises incorporating the one or more pacing electrodes onto a distal end portion of a stent delivery catheter.
  • 18. The method of claim 14, wherein incorporating the one or more pacing electrodes onto the distal end portion of the PTVI device comprises incorporating the one or more pacing electrodes onto a distal end portion of a coronary brachytherapy catheter.
  • 19. The method of claim 14, wherein incorporating the one or more pacing electrodes onto the distal end portion of the PTVI device comprises incorporating the one or more pacing electrodes onto a distal end portion of an atherectomy device.
  • 20. The method of claim 14, wherein incorporating the one or more pacing electrodes onto the distal end portion of the PTVI device comprises incorporating the one or more pacing electrodes onto a distal end portion of a distal embolization protection device.
CLAIM OF PRIORITY

This application is a continuation of and claims the benefit of priority under 35 U.S.C. §120 to U.S. patent application Ser. No. 13/838,599, filed on Mar. 15, 2013, now issued as U.S. Pat. No. 9,415,225, which is a continuation of and claims the benefit of priority under 35 U.S.C. §120 to U.S. patent application Ser. No. 13/113,706, filed on May 23, 2011, now issued as U.S. Pat. No. 8,452,400, which is a continuation of and claims the benefit of priority under 35 U.S.C. §120 to U.S. patent application Ser. No. 11/113,828, filed on Apr. 25, 2005, now issued as U.S. Pat. No. 7,962,208, which is hereby incorporated by reference herein in its entirety.

US Referenced Citations (1037)
Number Name Date Kind
15192 Peale Jun 1856 A
2682057 Lord Jun 1954 A
2701559 Cooper Feb 1955 A
2832076 Polachek et al. Apr 1958 A
3099016 Edwards Jul 1963 A
3111358 Doerr Nov 1963 A
3130418 Head et al. Apr 1964 A
3143742 Cromie Aug 1964 A
3334629 Cohn Aug 1967 A
3367364 Cruz et al. Feb 1968 A
3409013 Berry Nov 1968 A
3445916 Schulte May 1969 A
3540431 Mobin-Uddin Nov 1970 A
3548417 Kischer Dec 1970 A
3570014 Hancock Mar 1971 A
3587115 Shiley Jun 1971 A
3592184 Watkins et al. Jul 1971 A
3628535 Ostrowsky et al. Dec 1971 A
3642004 Osthagen et al. Feb 1972 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3755823 Hancock Sep 1973 A
3769984 Muench Nov 1973 A
3795246 Sturgeon Mar 1974 A
3837347 Tower Sep 1974 A
3839741 Haller Oct 1974 A
3865118 Bures Feb 1975 A
3868956 Alfidi et al. Mar 1975 A
3874388 King et al. Apr 1975 A
3893461 Preston Jul 1975 A
3915174 Preston Oct 1975 A
3942536 Mirowski et al. Mar 1976 A
3949757 Sabel Apr 1976 A
3997923 Possis et al. Dec 1976 A
4030508 Thalen Jun 1977 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4094321 Muto Jun 1978 A
4106129 Carpentier et al. Aug 1978 A
4124031 Mensink et al. Nov 1978 A
4136702 Trabucco Jan 1979 A
4202339 Wirtzfeld et al. May 1980 A
4222126 Boretos et al. Sep 1980 A
4233690 Akins Nov 1980 A
4262982 Kenny Apr 1981 A
4265694 Boretos et al. May 1981 A
4291420 Reul Sep 1981 A
4297749 Davis et al. Nov 1981 A
4323358 Lentz et al. Apr 1982 A
4326306 Poler Apr 1982 A
4339831 Johnson Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4365639 Goldreyer Dec 1982 A
4373216 Klawitter Feb 1983 A
4388930 De Bellis Jun 1983 A
4406022 Roy Sep 1983 A
4423809 Mazzocco Jan 1984 A
4425908 Simon Jan 1984 A
4470157 Love Sep 1984 A
4484579 Meno et al. Nov 1984 A
4501030 Lane Feb 1985 A
4531943 Van Tassel et al. Jul 1985 A
4535483 Klawitter et al. Aug 1985 A
4574803 Storz Mar 1986 A
4580568 Gianturco Apr 1986 A
4587975 Salo et al. May 1986 A
4592340 Boyles Jun 1986 A
4602911 Ahmadi et al. Jul 1986 A
4605407 Black et al. Aug 1986 A
4610688 Silvestrini et al. Sep 1986 A
4612011 Kautzky Sep 1986 A
4617932 Kornberg Oct 1986 A
4643732 Pietsch et al. Feb 1987 A
4647283 Carpentier et al. Mar 1987 A
4648881 Carpentier et al. Mar 1987 A
4655218 Kulik et al. Apr 1987 A
4655771 Wallsten Apr 1987 A
4662885 DiPisa, Jr. May 1987 A
4665906 Jervis May 1987 A
4680031 Alonso Jul 1987 A
4692164 Dzemeshkevich et al. Sep 1987 A
4702253 Nappholz et al. Oct 1987 A
4705516 Barone et al. Nov 1987 A
4710192 Liotta et al. Dec 1987 A
4733665 Palmaz Mar 1988 A
4755181 Igoe Jul 1988 A
4759758 Gabbay Jul 1988 A
4763655 Wirtzfeld et al. Aug 1988 A
4777951 Cribier et al. Oct 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4809697 Causey, III et al. Mar 1989 A
4811975 Paul, Jr. et al. Mar 1989 A
4829990 Thuroff et al. May 1989 A
4834710 Fleck May 1989 A
4834755 Silvestrini et al. May 1989 A
4851001 Taheri Jul 1989 A
4856516 Hillstead Aug 1989 A
4865600 Carpentier et al. Sep 1989 A
4872874 Taheri Oct 1989 A
4873978 Ginsburg Oct 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4882777 Narula Nov 1989 A
4883458 Shiber Nov 1989 A
4885005 Nashef et al. Dec 1989 A
4909252 Goldberger Mar 1990 A
4917102 Miller et al. Apr 1990 A
4919133 Chiang Apr 1990 A
4922905 Strecker May 1990 A
4927426 Dretler May 1990 A
4954126 Wallsten Sep 1990 A
4962767 Brownlee Oct 1990 A
4966604 Reiss Oct 1990 A
4969890 Sugita et al. Nov 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5002556 Ishida et al. Mar 1991 A
5002559 Tower Mar 1991 A
5007427 Sukuki et al. Apr 1991 A
5007896 Shiber Apr 1991 A
5025786 Siegel Jun 1991 A
5026366 Leckrone Jun 1991 A
5032128 Alonso Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5064435 Porter Nov 1991 A
5072458 Suzuki Dec 1991 A
5080668 Bolz et al. Jan 1992 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5099839 Miyata et al. Mar 1992 A
5111818 Suzuki et al. May 1992 A
5121750 Katims Jun 1992 A
5127403 Brownlee Jul 1992 A
5131406 Kaltenbach Jul 1992 A
5132473 Furutaka et al. Jul 1992 A
5141494 Danforth et al. Aug 1992 A
5143089 Alt Sep 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5154169 Miyata et al. Oct 1992 A
5154387 Trailer Oct 1992 A
5156157 Valenta, Jr. et al. Oct 1992 A
5159937 Tremulis Nov 1992 A
5161547 Tower Nov 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5170802 Mehra Dec 1992 A
5209741 Spaeth May 1993 A
5215541 Nashef Jun 1993 A
5217483 Tower Jun 1993 A
5258023 Reger Nov 1993 A
5258042 Mehta Nov 1993 A
5261419 Osypka Nov 1993 A
5282847 Trescony et al. Feb 1994 A
5285781 Brodard Feb 1994 A
5295958 Shturman Mar 1994 A
5314460 Borghi May 1994 A
5332402 Teitelbaum Jul 1994 A
5334221 Bardy Aug 1994 A
5336251 Borghi Aug 1994 A
5336258 Quintero et al. Aug 1994 A
5350398 Pavcnik et al. Sep 1994 A
5356427 Miyata et al. Oct 1994 A
5360444 Kusuhara Nov 1994 A
5370685 Stevens Dec 1994 A
5374287 Rubin Dec 1994 A
5387232 Trailer Feb 1995 A
5389106 Tower Feb 1995 A
5397351 Pavcnik et al. Mar 1995 A
5409019 Wilk Apr 1995 A
5411535 Fujii et al. May 1995 A
5411552 Andersen et al. May 1995 A
5423806 Dale et al. Jun 1995 A
5425762 Muller Jun 1995 A
5431676 Dubrul et al. Jul 1995 A
5443446 Shturman Aug 1995 A
5443449 Buelna Aug 1995 A
5443477 Marin et al. Aug 1995 A
5443495 Buscemi et al. Aug 1995 A
5443499 Schmitt Aug 1995 A
5466255 Franchi Nov 1995 A
5476502 Rubin Dec 1995 A
5476506 Lunn Dec 1995 A
5476510 Eberhardt et al. Dec 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5480424 Cox Jan 1996 A
5483022 Mar Jan 1996 A
5484419 Fleck Jan 1996 A
5496354 DeBellis Mar 1996 A
5500014 Quijano et al. Mar 1996 A
5507767 Maeda et al. Apr 1996 A
5507787 Borghi Apr 1996 A
5531779 Dahl et al. Jul 1996 A
5534007 St. Germain et al. Jul 1996 A
5545133 Burns et al. Aug 1996 A
5545191 Mann et al. Aug 1996 A
5545209 Roberts Aug 1996 A
5545211 An et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5554185 Block et al. Sep 1996 A
5571159 Alt Nov 1996 A
5571175 Vanney et al. Nov 1996 A
5571215 Sterman et al. Nov 1996 A
5573520 Schwartz et al. Nov 1996 A
5575818 Pinchuk Nov 1996 A
5588432 Crowley Dec 1996 A
5591185 Kilmer et al. Jan 1997 A
5591195 Taheri et al. Jan 1997 A
5607464 Trescony et al. Mar 1997 A
5609626 Quijano et al. Mar 1997 A
5634899 Shapland et al. Jun 1997 A
5645559 Hachtman et al. Jul 1997 A
5662671 Barbut et al. Sep 1997 A
5667523 Bynon Sep 1997 A
5674217 Wahlstrom et al. Oct 1997 A
5674277 Freitag Oct 1997 A
5693083 Baker Dec 1997 A
5693310 Gries et al. Dec 1997 A
5695498 Tower Dec 1997 A
5709713 Evans et al. Jan 1998 A
5713951 Garrison et al. Feb 1998 A
5713953 Vallana et al. Feb 1998 A
5716370 Williamson, IV et al. Feb 1998 A
5716417 Girard et al. Feb 1998 A
5720391 Dohm et al. Feb 1998 A
5725549 Lam Mar 1998 A
5728068 Leone et al. Mar 1998 A
5733325 Robinson et al. Mar 1998 A
5735842 Krueger et al. Apr 1998 A
5749890 Shaknovich May 1998 A
5755761 Obino May 1998 A
5755764 Schroeppel May 1998 A
5756476 Epstein et al. May 1998 A
5760341 Laske et al. Jun 1998 A
5769812 Stevens et al. Jun 1998 A
5772693 Brownlee Jun 1998 A
5797903 Swanson et al. Aug 1998 A
5800456 Maeda et al. Sep 1998 A
5800496 Swoyer et al. Sep 1998 A
5800531 Cosgrove et al. Sep 1998 A
5807405 Vanney Sep 1998 A
5814076 Brownlee Sep 1998 A
5817126 Imran Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824043 Cottone, Jr. Oct 1998 A
5824053 Khosravi Oct 1998 A
5824055 Spiridigliozzi et al. Oct 1998 A
5824056 Rosenberg Oct 1998 A
5824064 Taheri Oct 1998 A
5840081 Andersen et al. Nov 1998 A
5843132 Ilvento Dec 1998 A
5843158 Lenker et al. Dec 1998 A
5851206 Guglielmi et al. Dec 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5855602 Angell Jan 1999 A
5860966 Tower Jan 1999 A
5861024 Rashidi Jan 1999 A
5861028 Angell Jan 1999 A
5868783 Tower Feb 1999 A
5876419 Carpenter et al. Mar 1999 A
5876448 Thompson et al. Mar 1999 A
5885228 Rosenmann et al. Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5891191 Stinson Apr 1999 A
5895399 Barbut et al. Apr 1999 A
5906207 Shen May 1999 A
5906619 Olson et al. May 1999 A
5907893 Zadno-Azizi et al. Jun 1999 A
5910154 Tsugita et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5921935 Hickey Jul 1999 A
5925063 Khosravi Jul 1999 A
5935160 Auricchio et al. Aug 1999 A
5944738 Amplatz Aug 1999 A
5954761 Machek et al. Sep 1999 A
5954766 Zadno-Azizi Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
5968070 Bley et al. Oct 1999 A
5984957 Laptewicz, Jr. et al. Nov 1999 A
5984959 Robertson et al. Nov 1999 A
5993469 McKenzie et al. Nov 1999 A
5997536 Osswald et al. Dec 1999 A
5997557 Barbut et al. Dec 1999 A
6010522 Barbut et al. Jan 2000 A
6014579 Pomeranz et al. Jan 2000 A
6022370 Tower Feb 2000 A
6023638 Swanson Feb 2000 A
6027520 Tsugita et al. Feb 2000 A
6027525 Suh et al. Feb 2000 A
6042598 Tsugita Mar 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6051014 Jang Apr 2000 A
6056742 Murphy-Chutorian et al. May 2000 A
6059827 Fenton, Jr. May 2000 A
6074418 Buchanan et al. Jun 2000 A
6093203 Uflacker Jul 2000 A
6096074 Pedros Aug 2000 A
6123723 Konya Sep 2000 A
6132390 Cookston et al. Oct 2000 A
6132473 Williams Oct 2000 A
6142987 Tsugita Nov 2000 A
6146366 Schachar Nov 2000 A
6156061 Wallace et al. Dec 2000 A
6161029 Spreigl et al. Dec 2000 A
6162245 Jayaraman Dec 2000 A
6165200 Tsugita et al. Dec 2000 A
6165209 Patterson et al. Dec 2000 A
6167315 Coe et al. Dec 2000 A
6168579 Tsugita Jan 2001 B1
6168614 Andersen Jan 2001 B1
6171327 Daniel et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6178354 Gibson Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6183469 Thapliyal et al. Feb 2001 B1
6187016 Hedges et al. Feb 2001 B1
6197053 Cosgrove et al. Mar 2001 B1
6200336 Pavcnik et al. Mar 2001 B1
6214036 Letendre et al. Apr 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6221096 Aiba et al. Apr 2001 B1
6221100 Strecker Apr 2001 B1
6231544 Tsugita et al. May 2001 B1
6231551 Barbut May 2001 B1
6238390 Tu et al. May 2001 B1
6241727 Tu et al. Jun 2001 B1
6241757 An et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6251135 Stinson et al. Jun 2001 B1
6258114 Konya et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258120 McKenzie et al. Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6270513 Tsugita et al. Aug 2001 B1
6272379 Fischell et al. Aug 2001 B1
6277555 Duran et al. Aug 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6309417 Spence et al. Oct 2001 B1
6319281 Patel et al. Nov 2001 B1
6324434 Coe et al. Nov 2001 B2
6327772 Zadno-Azizi et al. Dec 2001 B1
6336934 Gilson et al. Jan 2002 B1
6336937 Vonesh et al. Jan 2002 B1
6338735 Stevens Jan 2002 B1
6346116 Brooks et al. Feb 2002 B1
6348063 Yassour et al. Feb 2002 B1
6352554 De Paulis Mar 2002 B2
6352708 Duran et al. Mar 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6363938 Saadat et al. Apr 2002 B2
6364895 Greenhalgh Apr 2002 B1
6366808 Schroeppel et al. Apr 2002 B1
6371970 Khosravi et al. Apr 2002 B1
6371983 Lane Apr 2002 B1
6379351 Thapliyal et al. Apr 2002 B1
6379383 Palmaz et al. Apr 2002 B1
6397109 Cammilli et al. May 2002 B1
6398807 Chouinard et al. Jun 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6416510 Altman et al. Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 Dimatteo et al. Aug 2002 B1
6449507 Hill et al. Sep 2002 B1
6451016 Karakozian Sep 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6468303 Amplatz et al. Oct 2002 B1
6468660 Ogle Oct 2002 B2
6475239 Campbell et al. Nov 2002 B1
6477402 Lynch et al. Nov 2002 B1
6477427 Stolz et al. Nov 2002 B1
6482228 Norred Nov 2002 B1
6485501 Green et al. Nov 2002 B1
6485502 Don Michael et al. Nov 2002 B2
6488704 Connelly et al. Dec 2002 B1
6494909 Greenhalgh Dec 2002 B2
6501983 Natarajan et al. Dec 2002 B1
6503272 Duerig et al. Jan 2003 B2
6508833 Pavcnik et al. Jan 2003 B2
6512957 Witte Jan 2003 B1
6527800 McGuckin, Jr. et al. Mar 2003 B1
6530949 Knoya et al. Mar 2003 B2
6530952 Vesely Mar 2003 B2
6532388 Hill et al. Mar 2003 B1
6537297 Tsugita et al. Mar 2003 B2
6540765 Malacoff Apr 2003 B1
6540768 Diaz et al. Apr 2003 B1
6542774 Hill et al. Apr 2003 B2
6562058 Seguin et al. May 2003 B2
6569145 Shmulewitz et al. May 2003 B1
6569196 Vesely May 2003 B1
6572643 Gharibadeh Jun 2003 B1
6584362 Scheiner et al. Jun 2003 B1
6592546 Barbut et al. Jul 2003 B1
6592614 Lenker Jul 2003 B2
6605112 Moll et al. Aug 2003 B1
6610077 Hancock et al. Aug 2003 B1
6616682 Joergensen et al. Sep 2003 B2
6622604 Chouinard et al. Sep 2003 B1
6623518 Thompson et al. Sep 2003 B2
6623521 Steinke et al. Sep 2003 B2
6628987 Hill et al. Sep 2003 B1
6632243 Zadno-Azizi et al. Oct 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6635079 Unsworth et al. Oct 2003 B2
6638278 Falwell et al. Oct 2003 B2
6640120 Swanson et al. Oct 2003 B1
6652571 White et al. Nov 2003 B1
6652578 Bailey et al. Nov 2003 B2
6663588 DuBois et al. Dec 2003 B2
6663663 Kim et al. Dec 2003 B2
6669724 Park et al. Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6673109 Cox Jan 2004 B2
6676668 Mercereau et al. Jan 2004 B2
6676692 Rabkin et al. Jan 2004 B2
6676698 McGuckin, Jr. et al. Jan 2004 B2
6682543 Barbut et al. Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers et al. Jan 2004 B2
6685739 DiMatteo et al. Feb 2004 B2
6689144 Gerberding Feb 2004 B2
6689164 Seguin Feb 2004 B1
6690970 Taheri et al. Feb 2004 B1
6692512 Jang Feb 2004 B2
6695864 Macoviak et al. Feb 2004 B2
6695865 Boyle et al. Feb 2004 B2
6697676 Dahl Feb 2004 B2
6702851 Chinn et al. Mar 2004 B1
6709390 Marie Pop Mar 2004 B1
6711436 Duhaylongsod Mar 2004 B1
6711440 Deal et al. Mar 2004 B2
6712842 Gifford et al. Mar 2004 B1
6712843 Elliott Mar 2004 B2
6714842 Ito Mar 2004 B1
6718208 Hill et al. Apr 2004 B2
6719789 Cox Apr 2004 B2
6723116 Taheri Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6730377 Wang May 2004 B2
6733525 Yang et al. May 2004 B2
6735471 Hill et al. May 2004 B2
6736846 Cox May 2004 B2
6752828 Thornton Jun 2004 B2
6755854 Gillick et al. Jun 2004 B2
6758855 Fulton, III et al. Jul 2004 B2
6764503 Ishimaru Jul 2004 B1
6764509 Chinn et al. Jul 2004 B2
6767345 St. Germain et al. Jul 2004 B2
6769434 Liddicoat et al. Aug 2004 B2
6772014 Coe et al. Aug 2004 B2
6773454 Wholey et al. Aug 2004 B2
6776791 Stallings et al. Aug 2004 B1
6786925 Schoon et al. Sep 2004 B1
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6790237 Stinson Sep 2004 B2
6792979 Konya et al. Sep 2004 B2
6797002 Spence et al. Sep 2004 B2
RE38654 Hill et al. Nov 2004 E
6813516 Ujhelyi et al. Nov 2004 B2
6814746 Thompson et al. Nov 2004 B2
6821297 Snyders Nov 2004 B2
6830585 Artof et al. Dec 2004 B1
6837901 Rabkin et al. Jan 2005 B2
6840957 DiMatteo et al. Jan 2005 B2
6843802 Villalobos et al. Jan 2005 B1
RE38705 Hill et al. Feb 2005 E
6849085 Marton Feb 2005 B2
6863668 Gillespie et al. Mar 2005 B2
6865420 Kroll Mar 2005 B1
6866650 Stevens et al. Mar 2005 B2
6866669 Buzzard Mar 2005 B2
6872223 Roberts et al. Mar 2005 B2
6872226 Cali Mar 2005 B2
6875231 Anduiza Apr 2005 B2
6881220 Edwin et al. Apr 2005 B2
6887266 Williams et al. May 2005 B2
6890340 Duane May 2005 B2
6893459 Macoviak May 2005 B1
6893460 Spenser et al. May 2005 B2
6904318 Hill et al. Jun 2005 B2
6905743 Chen et al. Jun 2005 B1
6908481 Cribier Jun 2005 B2
6909920 Lokhoff et al. Jun 2005 B2
6911036 Douk et al. Jun 2005 B2
6911043 Myers et al. Jun 2005 B2
6912419 Hill et al. Jun 2005 B2
6936058 Forde et al. Aug 2005 B2
6936067 Buchanan Aug 2005 B2
6939352 Buzzard Sep 2005 B2
6950701 Begemann et al. Sep 2005 B2
6951571 Srivastava Oct 2005 B1
6953332 Kurk Oct 2005 B1
6964673 Tsugita et al. Nov 2005 B2
6969395 Eskuri Nov 2005 B2
6972025 WasDyke et al. Dec 2005 B2
6974464 Quijano et al. Dec 2005 B2
6974474 Pavcnik et al. Dec 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
6979350 Moll et al. Dec 2005 B2
6980858 Fuimaono et al. Dec 2005 B2
6984242 Campbell Jan 2006 B2
6988001 Greatbatch et al. Jan 2006 B2
6989027 Allen Jan 2006 B2
6994314 Garnier et al. Feb 2006 B2
6999809 Currier et al. Feb 2006 B2
6999821 Jenney et al. Feb 2006 B2
7003350 Denker et al. Feb 2006 B2
7004176 Lau Feb 2006 B2
7011681 Vesely Mar 2006 B2
7018406 Seguin et al. Mar 2006 B2
7025791 Levine et al. Apr 2006 B2
7029467 Currier et al. Apr 2006 B2
7037331 Mitelberg et al. May 2006 B2
7041132 Quijano et al. May 2006 B2
7097658 Oktay Aug 2006 B2
7115141 Menz et al. Oct 2006 B2
7122020 Mogul Oct 2006 B2
7125418 Duran et al. Oct 2006 B2
7141063 White et al. Nov 2006 B2
7166097 Barbut Jan 2007 B2
7175653 Gaber Feb 2007 B2
7175654 Bonsignore et al. Feb 2007 B2
7175656 Khairkhahan Feb 2007 B2
7184829 Hill et al. Feb 2007 B2
7189258 Johnson et al. Mar 2007 B2
7191018 Gielen et al. Mar 2007 B2
7201772 Schwammenthal Apr 2007 B2
7225019 Jahns et al. May 2007 B2
7235093 Gregorich Jun 2007 B2
7236821 Cates et al. Jun 2007 B2
7258696 Rabkin et al. Aug 2007 B2
7267686 DiMatteo et al. Sep 2007 B2
7269457 Shafer et al. Sep 2007 B2
7276078 Spenser et al. Oct 2007 B2
7295874 Prinzen et al. Nov 2007 B2
7322932 Xie et al. Jan 2008 B2
7326236 Andreas et al. Feb 2008 B2
7329279 Haug Feb 2008 B2
7374560 Ressemann et al. May 2008 B2
7381219 Salahieh et al. Jun 2008 B2
7381220 Macoviak et al. Jun 2008 B2
7399315 Iobbi Jul 2008 B2
7422585 Eggers et al. Sep 2008 B1
7445631 Salahieh et al. Nov 2008 B2
7470285 Nugent Dec 2008 B2
7473417 Zeltinger et al. Jan 2009 B2
7491232 Bolduc et al. Feb 2009 B2
7499756 Bowe et al. Mar 2009 B2
7510574 L et al. Mar 2009 B2
7524330 Berreklouw Apr 2009 B2
7530995 Quijano et al. May 2009 B2
7544206 Cohn Jun 2009 B2
7570981 Peterson Aug 2009 B2
7601159 Ewers Oct 2009 B2
7622276 Cunanan et al. Nov 2009 B2
7628802 White et al. Dec 2009 B2
7628803 Pavcnik et al. Dec 2009 B2
7632298 Hijlkema Dec 2009 B2
7641687 Chinn et al. Jan 2010 B2
7674282 Wu et al. Mar 2010 B2
7697984 Hill et al. Apr 2010 B2
7711421 Shafer et al. May 2010 B2
7712606 Salahieh et al. May 2010 B2
7722638 Deyette, Jr. May 2010 B2
7722662 Steinke May 2010 B2
7722666 Lafontaine May 2010 B2
7736388 Goldfarb Jun 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7758625 Wu et al. Jul 2010 B2
7763065 Schmid et al. Jul 2010 B2
7780725 Haug et al. Aug 2010 B2
7799065 Pappas Sep 2010 B2
7803185 Gabbay et al. Sep 2010 B2
7824442 Salahieh et al. Nov 2010 B2
7824443 Salahieh et al. Nov 2010 B2
7833262 McGuckin, Jr. Nov 2010 B2
7846204 Letac Dec 2010 B2
7857845 Stacchino et al. Dec 2010 B2
7892292 Stack et al. Feb 2011 B2
7914574 Schmid Mar 2011 B2
7917210 Baynham et al. Mar 2011 B2
7918880 Austin Apr 2011 B2
7927363 Perouse Apr 2011 B2
7938851 Olson et al. May 2011 B2
7959666 Salahieh et al. Jun 2011 B2
7959672 Salahieh et al. Jun 2011 B2
7962208 Shuros et al. Jun 2011 B2
7967853 Eidenschink et al. Jun 2011 B2
7979123 Prinzen et al. Jul 2011 B2
7988724 Salahieh et al. Aug 2011 B2
8027723 Pastore Sep 2011 B2
8036741 Jahns et al. Oct 2011 B2
8048153 Salahieh et al. Nov 2011 B2
8052749 Salahieh et al. Nov 2011 B2
8167894 Miles et al. May 2012 B2
8182528 Salahieh et al. May 2012 B2
8214040 Pastore et al. Jul 2012 B2
8226710 Nguyen et al. Jul 2012 B2
8231670 Salahieh Jul 2012 B2
8244352 Eidenschink et al. Aug 2012 B2
8246678 Salahieh et al. Aug 2012 B2
8252052 Salahieh et al. Aug 2012 B2
8277500 Schmid et al. Oct 2012 B2
8328868 Paul et al. Dec 2012 B2
8343213 Salahieh et al. Jan 2013 B2
8348999 Kheradvar et al. Jan 2013 B2
8376865 Forster et al. Feb 2013 B2
8579962 Salahieh et al. Nov 2013 B2
8603160 Salahieh et al. Dec 2013 B2
8617236 Paul et al. Dec 2013 B2
8623076 Salahieh et al. Jan 2014 B2
8623078 Salahieh et al. Jan 2014 B2
8668733 Haug Mar 2014 B2
8828078 Salahieh et al. Sep 2014 B2
8840662 Salahieh et al. Sep 2014 B2
8840663 Salahieh et al. Sep 2014 B2
8855762 Baynham et al. Oct 2014 B2
8858620 Salahieh et al. Oct 2014 B2
9005273 Salahieh et al. Apr 2015 B2
9037235 Tomaschko et al. May 2015 B2
20010002445 Vesely May 2001 A1
20010007956 Letac et al. Jul 2001 A1
20010010017 Letac Jul 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20010025196 Chinn et al. Sep 2001 A1
20010032013 Marton Oct 2001 A1
20010039450 Pavcnik et al. Nov 2001 A1
20010041928 Pavcnik et al. Nov 2001 A1
20010041930 Globerman et al. Nov 2001 A1
20010044634 Don Michael et al. Nov 2001 A1
20010044652 Moore Nov 2001 A1
20010044656 Williamson, IV et al. Nov 2001 A1
20020002396 Fulkerson Jan 2002 A1
20020010489 Grayzel et al. Jan 2002 A1
20020026228 Schauerte Feb 2002 A1
20020026233 Shaknovich Feb 2002 A1
20020029014 Jayaraman Mar 2002 A1
20020029981 Nigam Mar 2002 A1
20020032480 Spence et al. Mar 2002 A1
20020032481 Gabbay Mar 2002 A1
20020042632 Iaizzo et al. Apr 2002 A1
20020042651 Liddicoat et al. Apr 2002 A1
20020052651 Myers et al. May 2002 A1
20020055767 Forde et al. May 2002 A1
20020055769 Wang May 2002 A1
20020058995 Stevens May 2002 A1
20020072777 Lu Jun 2002 A1
20020077696 Zadno-Azizi et al. Jun 2002 A1
20020082609 Green Jun 2002 A1
20020095067 Guenst et al. Jul 2002 A1
20020095173 Mazzocchi et al. Jul 2002 A1
20020095209 Zadno-Azizi et al. Jul 2002 A1
20020111674 Chouinard et al. Aug 2002 A1
20020116028 Greatbatch et al. Aug 2002 A1
20020116029 Miller et al. Aug 2002 A1
20020116033 Greatbatch et al. Aug 2002 A1
20020116034 Miller et al. Aug 2002 A1
20020120328 Pathak et al. Aug 2002 A1
20020123802 Snyders Sep 2002 A1
20020138138 Yang Sep 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020161390 Mouw Oct 2002 A1
20020161392 Dubrul Oct 2002 A1
20020161394 Macoviak et al. Oct 2002 A1
20020165576 Boyle et al. Nov 2002 A1
20020177766 Mogul Nov 2002 A1
20020183781 Casey et al. Dec 2002 A1
20020188341 Elliott Dec 2002 A1
20020188344 Bolea et al. Dec 2002 A1
20020193871 Beyersdorf et al. Dec 2002 A1
20030004549 Hill et al. Jan 2003 A1
20030009189 Gilson et al. Jan 2003 A1
20030014104 Cribier Jan 2003 A1
20030023303 Palmaz et al. Jan 2003 A1
20030028247 Cali Feb 2003 A1
20030036791 Philipp et al. Feb 2003 A1
20030040736 Stevens et al. Feb 2003 A1
20030040771 Hyodoh et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030040791 Oktay Feb 2003 A1
20030040792 Gabbay Feb 2003 A1
20030045908 Condie et al. Mar 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030060821 Hall et al. Mar 2003 A1
20030060844 Borillo et al. Mar 2003 A1
20030060854 Zhu Mar 2003 A1
20030069492 Abrams et al. Apr 2003 A1
20030069646 Stinson Apr 2003 A1
20030070944 Nigam Apr 2003 A1
20030078471 Foley et al. Apr 2003 A1
20030100918 Duane May 2003 A1
20030100919 Hopkins et al. May 2003 A1
20030105493 Salo Jun 2003 A1
20030109901 Greatbatch Jun 2003 A1
20030109924 Cribier Jun 2003 A1
20030109930 Bluni et al. Jun 2003 A1
20030114912 Sequin et al. Jun 2003 A1
20030114913 Spenser et al. Jun 2003 A1
20030125774 Salo Jul 2003 A1
20030125795 Pavcnik et al. Jul 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030135257 Taheri Jul 2003 A1
20030139778 Fischell et al. Jul 2003 A1
20030144732 Cosgrove et al. Jul 2003 A1
20030149475 Hyodoh et al. Aug 2003 A1
20030149476 Damm et al. Aug 2003 A1
20030149478 Figulla et al. Aug 2003 A1
20030153974 Spenser et al. Aug 2003 A1
20030158583 Burnett et al. Aug 2003 A1
20030158584 Cates et al. Aug 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030181850 Diamond et al. Sep 2003 A1
20030187495 Cully et al. Oct 2003 A1
20030191516 Weldon et al. Oct 2003 A1
20030199913 Dubrul et al. Oct 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030199972 Zadno-Azizi et al. Oct 2003 A1
20030204206 Padua et al. Oct 2003 A1
20030204231 Hine et al. Oct 2003 A1
20030208224 Broome Nov 2003 A1
20030212361 Boyle et al. Nov 2003 A1
20030212429 Keegan et al. Nov 2003 A1
20030212452 Zadno-Azizi et al. Nov 2003 A1
20030212454 Scott et al. Nov 2003 A1
20030216774 Larson Nov 2003 A1
20030225445 Derus et al. Dec 2003 A1
20030229386 Rosenman et al. Dec 2003 A1
20030229390 Ashton et al. Dec 2003 A1
20030233117 Adams et al. Dec 2003 A1
20030233130 Padmanabhan et al. Dec 2003 A1
20040010189 van Sloun et al. Jan 2004 A1
20040015081 Kramer et al. Jan 2004 A1
20040015204 Whitehurst et al. Jan 2004 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040034411 Quijano et al. Feb 2004 A1
20040038947 Wink et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040049224 Buehlmann et al. Mar 2004 A1
20040049226 Keegan et al. Mar 2004 A1
20040049262 Obermiller et al. Mar 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040059409 Stenzel Mar 2004 A1
20040073198 Gilson et al. Apr 2004 A1
20040082904 Houde et al. Apr 2004 A1
20040082967 Broome et al. Apr 2004 A1
20040087982 Eskuri May 2004 A1
20040088017 Sharma et al. May 2004 A1
20040088045 Cox May 2004 A1
20040093016 Root et al. May 2004 A1
20040093060 Seguin et al. May 2004 A1
20040097788 Mourlas et al. May 2004 A1
20040098022 Barone May 2004 A1
20040098098 McGuckin, Jr. et al. May 2004 A1
20040098099 McCullagh et al. May 2004 A1
20040098112 DiMatteo et al. May 2004 A1
20040106960 Siejko et al. Jun 2004 A1
20040107004 Levine et al. Jun 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040116951 Rosengart Jun 2004 A1
20040116994 De Bellis Jun 2004 A1
20040117004 Osborne et al. Jun 2004 A1
20040117009 Cali et al. Jun 2004 A1
20040122468 Yodfat et al. Jun 2004 A1
20040122516 Fogarty et al. Jun 2004 A1
20040127936 Salahieh et al. Jul 2004 A1
20040127979 Wilson et al. Jul 2004 A1
20040133247 Stahmann et al. Jul 2004 A1
20040133274 Webler et al. Jul 2004 A1
20040138694 Tran et al. Jul 2004 A1
20040138742 Myers et al. Jul 2004 A1
20040138743 Myers et al. Jul 2004 A1
20040148018 Carpentier et al. Jul 2004 A1
20040148021 Cartledge et al. Jul 2004 A1
20040153094 Dunfee et al. Aug 2004 A1
20040158277 Lowe et al. Aug 2004 A1
20040162599 Kurth Aug 2004 A1
20040167565 Beulke et al. Aug 2004 A1
20040167620 Ortiz et al. Aug 2004 A1
20040172081 Wang Sep 2004 A1
20040181140 Falwell et al. Sep 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040186563 Lobbi Sep 2004 A1
20040193261 Berreklouw Sep 2004 A1
20040199245 Lauterjung Oct 2004 A1
20040204755 Robin Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040210306 Quijano Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040214148 Salvino et al. Oct 2004 A1
20040215139 Cohen Oct 2004 A1
20040215331 Chew et al. Oct 2004 A1
20040215333 Duran et al. Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040220655 Swanson et al. Nov 2004 A1
20040225321 Krolik et al. Nov 2004 A1
20040225353 McGuckin, Jr. et al. Nov 2004 A1
20040225354 Allen Nov 2004 A1
20040225355 Stevens Nov 2004 A1
20040243221 Fawzi et al. Dec 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20040255956 Vinten-Johansen et al. Dec 2004 A1
20040260390 Sara Dec 2004 A1
20040267326 Ocel Dec 2004 A1
20050004476 Payvar et al. Jan 2005 A1
20050010287 Macoviak et al. Jan 2005 A1
20050021136 Xie et al. Jan 2005 A1
20050033398 Seguin Feb 2005 A1
20050033402 Cully, II et al. Feb 2005 A1
20050038345 Gorgenberg et al. Feb 2005 A1
20050043711 Corcoran et al. Feb 2005 A1
20050043757 Arad et al. Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050049692 Numamoto et al. Mar 2005 A1
20050049696 Siess et al. Mar 2005 A1
20050055088 Liddicoat et al. Mar 2005 A1
20050060016 Wu et al. Mar 2005 A1
20050060029 Le et al. Mar 2005 A1
20050065594 DiMatteo et al. Mar 2005 A1
20050075584 Cali Apr 2005 A1
20050075662 Pedersen et al. Apr 2005 A1
20050075673 Warkentin et al. Apr 2005 A1
20050075712 Biancucci et al. Apr 2005 A1
20050075717 Nguyen Apr 2005 A1
20050075719 Bergheim Apr 2005 A1
20050075724 Svanidze et al. Apr 2005 A1
20050075730 Myers et al. Apr 2005 A1
20050075731 Artof et al. Apr 2005 A1
20050085841 Eversull Apr 2005 A1
20050085842 Eversull Apr 2005 A1
20050085843 Opolski Apr 2005 A1
20050085890 Rasmussen Apr 2005 A1
20050090846 Pedersen et al. Apr 2005 A1
20050090890 Wu et al. Apr 2005 A1
20050096692 Linder et al. May 2005 A1
20050096734 Majercak May 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096736 Osse et al. May 2005 A1
20050096738 Cali May 2005 A1
20050100580 Osborne May 2005 A1
20050107822 WasDyke May 2005 A1
20050113910 Paniagua et al. May 2005 A1
20050119545 Swanson Jun 2005 A1
20050131438 Cohn et al. Jun 2005 A1
20050137483 Fischell et al. Jun 2005 A1
20050137631 Yu et al. Jun 2005 A1
20050137647 Wallace et al. Jun 2005 A1
20050137683 Hezi-Yamit et al. Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137687 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137692 Haug et al. Jun 2005 A1
20050137693 Haug Jun 2005 A1
20050137694 Haug Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050137699 Salahieh et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050137702 Haug et al. Jun 2005 A1
20050143780 Henry et al. Jun 2005 A1
20050143807 Pavcnik et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050149155 Scheiner et al. Jul 2005 A1
20050149159 Andreas et al. Jul 2005 A1
20050165352 Henry et al. Jul 2005 A1
20050165477 Anduiza et al. Jul 2005 A1
20050165479 Drews et al. Jul 2005 A1
20050182486 Gabbay Aug 2005 A1
20050197674 McCabe et al. Sep 2005 A1
20050197694 Pai et al. Sep 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050203614 Forster Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203616 Cribier Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050203618 Sharkawy et al. Sep 2005 A1
20050209580 Freyman Sep 2005 A1
20050222632 Obino Oct 2005 A1
20050228472 Case et al. Oct 2005 A1
20050228495 Macoviak Oct 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050240262 White Oct 2005 A1
20050251239 Wallace et al. Nov 2005 A1
20050251250 Verhoeven et al. Nov 2005 A1
20050251251 Cribier Nov 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050267560 Bates Dec 2005 A1
20050283231 Haug et al. Dec 2005 A1
20050283962 Boudjemline Dec 2005 A1
20050288717 Sunagawa Dec 2005 A1
20050288763 Andreas et al. Dec 2005 A1
20060004439 Spenser et al. Jan 2006 A1
20060004442 Spenser et al. Jan 2006 A1
20060009830 Atkinson et al. Jan 2006 A1
20060015168 Gunderson Jan 2006 A1
20060036306 Heist et al. Feb 2006 A1
20060058597 Machado et al. Mar 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060100639 Levin et al. May 2006 A1
20060100669 Fuimaono et al. May 2006 A1
20060116593 Zhang et al. Jun 2006 A1
20060136049 Rojo Jun 2006 A1
20060142660 Maschke Jun 2006 A1
20060142812 Ortega et al. Jun 2006 A1
20060149326 Prinzen et al. Jul 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060155312 Levine et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060173524 Salahieh et al. Aug 2006 A1
20060178586 Dobak, III Aug 2006 A1
20060184191 O'Brien Aug 2006 A1
20060195038 Carlson et al. Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060241357 Chirife Oct 2006 A1
20060241704 Shuros et al. Oct 2006 A1
20060241733 Zhang et al. Oct 2006 A1
20060241736 Haldeman Oct 2006 A1
20060247700 Jackson Nov 2006 A1
20060253156 Pastore et al. Nov 2006 A1
20060253191 Salahieh et al. Nov 2006 A1
20060259085 Zhang et al. Nov 2006 A1
20060259087 Baynham et al. Nov 2006 A1
20060259088 Pastore et al. Nov 2006 A1
20060259134 Schwammenthal et al. Nov 2006 A1
20060271166 Thill et al. Nov 2006 A1
20060287668 Fawzi et al. Dec 2006 A1
20060287684 Baynham et al. Dec 2006 A1
20060287717 Rowe et al. Dec 2006 A1
20060293741 Johnson et al. Dec 2006 A1
20070010876 Salahieh Jan 2007 A1
20070010877 Salahieh et al. Jan 2007 A1
20070016286 Herrmann et al. Jan 2007 A1
20070021789 Pastore et al. Jan 2007 A1
20070055334 Haldeman et al. Mar 2007 A1
20070055340 Pryor et al. Mar 2007 A1
20070061008 Salahieh Mar 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20070100410 Lamson et al. May 2007 A1
20070100427 Perouse May 2007 A1
20070112355 Salahieh et al. May 2007 A1
20070118214 Salahieh et al. May 2007 A1
20070150005 Sih et al. Jun 2007 A1
20070150009 Kveen et al. Jun 2007 A1
20070162107 Haug et al. Jul 2007 A1
20070173918 Dreher et al. Jul 2007 A1
20070203503 Salahieh Aug 2007 A1
20070233200 Maschke Oct 2007 A1
20070244552 Salahieh et al. Oct 2007 A1
20070288089 Gurskis Dec 2007 A1
20080009940 Cribier Jan 2008 A1
20080033541 Gelbart Feb 2008 A1
20080058757 Pajunk et al. Mar 2008 A1
20080071315 Baynham et al. Mar 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080082136 Gaudiani Apr 2008 A1
20080082165 Wilson et al. Apr 2008 A1
20080109063 Hancock et al. May 2008 A1
20080114408 Shuros et al. May 2008 A1
20080125859 Salahieh et al. May 2008 A1
20080188928 Salahieh et al. Aug 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080221672 Lamphere Sep 2008 A1
20080234814 Salahieh et al. Sep 2008 A1
20080269878 Iobbi Oct 2008 A1
20080288030 Zhang et al. Nov 2008 A1
20080288054 Pulnev et al. Nov 2008 A1
20080319502 Sunagawa et al. Dec 2008 A1
20090005845 David et al. Jan 2009 A1
20090005863 Goetz et al. Jan 2009 A1
20090030512 Thielen et al. Jan 2009 A1
20090054969 Salahieh Feb 2009 A1
20090076598 Salahieh et al. Mar 2009 A1
20090143835 Pastore et al. Jun 2009 A1
20090171456 Kveen Jul 2009 A1
20090222076 Figulla et al. Sep 2009 A1
20090264997 Salahieh Oct 2009 A1
20090299462 Fawzi Dec 2009 A1
20090318943 Eidenschink et al. Dec 2009 A1
20090318984 Mokelke et al. Dec 2009 A1
20090318989 Tomaschko et al. Dec 2009 A1
20090318990 Tomaschko et al. Dec 2009 A1
20090318991 Tomaschko et al. Dec 2009 A1
20090318992 Eidenschink et al. Dec 2009 A1
20090318993 Eidenschink et al. Dec 2009 A1
20090318994 Eidenschink et al. Dec 2009 A1
20100056858 Mokelke et al. Mar 2010 A1
20100094399 Dorn et al. Apr 2010 A1
20100121434 Paul et al. May 2010 A1
20100130913 Baynham et al. May 2010 A1
20100219092 Salahieh Sep 2010 A1
20100280495 Paul et al. Nov 2010 A1
20110137363 Baynham et al. Jun 2011 A1
20110144709 Baynham et al. Jun 2011 A1
20110230928 Shuros et al. Sep 2011 A1
20110257735 Salahieh et al. Oct 2011 A1
20110288634 Tuval et al. Nov 2011 A1
20120022642 Haug et al. Jan 2012 A1
20120029627 Salahieh et al. Feb 2012 A1
20120041550 Salahieh et al. Feb 2012 A1
20120053683 Salahieh et al. Mar 2012 A1
20120089224 Haug Apr 2012 A1
20120303113 Benichou Nov 2012 A1
20120330409 Haug et al. Dec 2012 A1
20130018457 Gregg Jan 2013 A1
20130123898 Tung et al. May 2013 A1
20130158656 Sutton et al. Jun 2013 A1
20130190865 Anderson Jul 2013 A1
20130268014 Shuros et al. Oct 2013 A1
20130304199 Sutton et al. Nov 2013 A1
20140018911 Zhou et al. Jan 2014 A1
20140094904 Salahieh et al. Apr 2014 A1
20140114405 Paul et al. Apr 2014 A1
20140114406 Salahieh et al. Apr 2014 A1
20140121766 Salahieh et al. May 2014 A1
20140135912 Salahieh et al. May 2014 A1
20140243967 Salahieh et al. Aug 2014 A1
Foreign Referenced Citations (162)
Number Date Country
2459408 Mar 2003 CA
3300050 Jul 1984 DE
19546692 Jun 1997 DE
19857887 Jul 2000 DE
19907646 Aug 2000 DE
10049812 Apr 2002 DE
10049813 Apr 2002 DE
10049814 Apr 2002 DE
10049815 Apr 2002 DE
103546 Mar 1984 EP
144167 Jun 1985 EP
0597967 May 1994 EP
0409929 Apr 1997 EP
0819013 Jan 1998 EP
0850607 Jul 1998 EP
1000590 May 2000 EP
1057459 Dec 2000 EP
1057460 Dec 2000 EP
1088529 Apr 2001 EP
937439 Sep 2003 EP
1340473 Sep 2003 EP
1356793 Oct 2003 EP
1042045 May 2004 EP
1430853 Jun 2004 EP
1435879 Jul 2004 EP
1439800 Jul 2004 EP
1472996 Nov 2004 EP
1229864 Apr 2005 EP
1059894 Jul 2005 EP
1551336 Jul 2005 EP
1078610 Aug 2005 EP
1562515 Aug 2005 EP
1576937 Sep 2005 EP
1582178 Oct 2005 EP
1582179 Oct 2005 EP
1469797 Nov 2005 EP
1589902 Nov 2005 EP
1600121 Nov 2005 EP
1156757 Dec 2005 EP
1616531 Jan 2006 EP
1690566 Aug 2006 EP
1605871 Jul 2008 EP
1570809 Jan 2009 EP
1551274 Dec 2014 EP
2788217 Jul 2000 FR
2056023 Mar 1981 GB
2398245 Aug 2004 GB
5245215 Sep 1993 JP
7504597 May 1995 JP
2002514478 May 2002 JP
2004533297 Nov 2004 JP
2006516451 Jul 2006 JP
2011524787 Sep 2011 JP
WO-9117720 Nov 1991 WO
WO-9217118 Oct 1992 WO
WO-9301768 Feb 1993 WO
WO-9315693 Aug 1993 WO
WO-9504556 Feb 1995 WO
WO-9518649 Jul 1995 WO
WO-9529640 Nov 1995 WO
WO-9614032 May 1996 WO
WO-9624306 Aug 1996 WO
WO-9640012 Dec 1996 WO
WO-9829057 Jul 1998 WO
WO-9836790 Aug 1998 WO
WO-9850103 Nov 1998 WO
WO-9857599 Dec 1998 WO
WO-9933414 Jul 1999 WO
WO-9940964 Aug 1999 WO
WO-9944542 Sep 1999 WO
WO-9947075 Sep 1999 WO
WO-9958191 Nov 1999 WO
WO-0009059 Feb 2000 WO
WO-0041652 Jul 2000 WO
WO-0044308 Aug 2000 WO
WO-0044311 Aug 2000 WO
WO-0044313 Aug 2000 WO
WO-0045874 Aug 2000 WO
WO-0047139 Aug 2000 WO
WO-0049970 Aug 2000 WO
WO-0067661 Nov 2000 WO
WO-0105331 Jan 2001 WO
WO-0108596 Feb 2001 WO
WO-0110320 Feb 2001 WO
WO-0110343 Feb 2001 WO
WO-0115609 Mar 2001 WO
WO-0135870 May 2001 WO
WO-0149213 Jul 2001 WO
WO-0154625 Aug 2001 WO
WO-0162189 Aug 2001 WO
WO-0164137 Sep 2001 WO
WO-0197715 Dec 2001 WO
WO-0236048 May 2002 WO
WO-0241789 May 2002 WO
WO-0243620 Jun 2002 WO
WO-0247575 Jun 2002 WO
WO-02100297 Dec 2002 WO
WO-03003943 Jan 2003 WO
WO-03003949 Jan 2003 WO
WO-03011195 Feb 2003 WO
WO-03015851 Feb 2003 WO
WO-03028592 Apr 2003 WO
WO-03030776 Apr 2003 WO
WO-03035139 May 2003 WO
WO-03037227 May 2003 WO
WO-03094793 Nov 2003 WO
WO-03094797 Nov 2003 WO
WO-2004014256 Feb 2004 WO
WO-2004019811 Mar 2004 WO
WO-2004023980 Mar 2004 WO
WO-2004026117 Apr 2004 WO
WO-2004041126 May 2004 WO
WO-2004047681 Jun 2004 WO
WO-2004058106 Jul 2004 WO
WO-2004058326 Jul 2004 WO
WO-2004058326 Jul 2004 WO
WO-2004066876 Aug 2004 WO
WO-2004082536 Sep 2004 WO
WO-2004089250 Oct 2004 WO
WO-2004089253 Oct 2004 WO
WO-2004093728 Nov 2004 WO
WO-2004096290 Nov 2004 WO
WO-2004105651 Dec 2004 WO
WO-2005000206 Jan 2005 WO
WO-2005002466 Jan 2005 WO
WO-2005004753 Jan 2005 WO
WO-2005009285 Feb 2005 WO
WO-2005011534 Feb 2005 WO
WO-2005011535 Feb 2005 WO
WO-2005023155 Mar 2005 WO
WO-2005027790 Mar 2005 WO
WO-2005042083 May 2005 WO
WO-2005046528 May 2005 WO
WO-2005046529 May 2005 WO
WO-2005048883 Jun 2005 WO
WO-2005062980 Jul 2005 WO
WO-2005065585 Jul 2005 WO
WO-2005065771 Jul 2005 WO
WO-2005084595 Sep 2005 WO
WO-2005087140 Sep 2005 WO
WO-2005096993 Oct 2005 WO
WO-2006009690 Jan 2006 WO
WO-2006027499 Mar 2006 WO
WO-2006115693 Nov 2006 WO
WO-2006115693 Nov 2006 WO
WO-2006124636 Nov 2006 WO
WO-2006124636 Nov 2006 WO
WO-2006124729 Nov 2006 WO
WO-2006124729 Nov 2006 WO
WO-2006138391 Dec 2006 WO
WO-2007033093 Mar 2007 WO
WO-2007035471 Mar 2007 WO
WO-2007044285 Apr 2007 WO
WO-2007053243 May 2007 WO
WO-2007058847 May 2007 WO
WO-2007092354 Aug 2007 WO
WO-2007097983 Aug 2007 WO
WO-2007133962 Nov 2007 WO
WO-2008027261 Mar 2008 WO
WO-2009154720 Dec 2009 WO
WO-2009154730 Dec 2009 WO
WO-2010042950 Apr 2010 WO
Non-Patent Literature Citations (257)
Entry
“U.S. Appl. No. 11/030,575, Non Final Office Action mailed Jul. 26, 2006”, 10 pgs.
“U.S. Appl. No. 11/030,575, Response filed Oct. 26, 2006 to Non Final Office Action mailed Jul. 26, 2006”, 8 pgs.
“U.S. Appl. No. 11/113,828, Advisory Action mailed Feb. 2, 2010”, 3 pgs.
“U.S. Appl. No. 11/113,828, Examiner Interview Summary mailed Feb. 4, 2011”, 1 pg.
“U.S. Appl. No. 11/113,828, Final Office Action mailed Jun. 29, 2009”, 11 pgs.
“U.S. Appl. No. 11/113,828, Final Office Action mailed Sep. 17, 2008”, 10 pgs.
“U.S. Appl. No. 11/113,828, Final Office Action mailed Nov. 24, 2009”, 13 pgs.
“U.S. Appl. No. 11/113,828, Non Final Office Action mailed Mar. 5, 2008”, 8 pgs.
“U.S. Appl. No. 11/113,828, Non Final Office Action mailed Dec. 22, 2008”, 10 pgs.
“U.S. Appl. No. 11/113,828, Notice of Allowance mailed Feb. 4, 2011”,7 pgs.
“U.S. Appl. No. 11/113,828, Notice of Allowance mailed Oct. 19, 2010”,4 pgs.
“U.S. Appl. No. 11/113,828, Response filed Jan. 25, 2010 to Final Office Action mailed Nov. 24, 2009”, 8 pgs.
“U.S. Appl. No. 11/113,828, Response filed Jan. 28, 2008 to Restriction Requirement mailed Dec. 26, 2007”, 7 pgs.
“U.S. Appl. No. 11/113,828, Response filed Mar. 23, 2009 to Non Final Office Action mailed Dec. 22, 2008”, 8 pgs.
“U.S. Appl. No. 11/113,828, Response filed Jun. 5, 2008 to Non Final Office Action mailed Mar. 5, 2008”, 8 pgs.
“U.S. Appl. No. 11/113,828, Response filed Oct. 29, 2009 to Final Office Action mailed Jun. 29, 2009”, 9 pgs.
“U.S. Appl. No. 11/113,828, Response filed Nov. 17, 2008 to Final Office Action mailed Sep. 17, 2008”, 11 pgs.
“U.S. Appl. No. 11/113,828, Restriction Requirementmailed Dec. 26, 2007”, 8 pgs.
“U.S. Appl. No. 11/129,050, Advisory Action mailed Jul. 14, 2009”, 3 pgs.
“U.S. Appl. No. 11/129,050, Examiner Interview Summary mailed Feb. 11, 2009”, 2 pgs.
“U.S. Appl. No. 11/129,050, Final Office Action mailed Apr. 21, 2009”, 10 pgs.
“U.S. Appl. No. 11/129,050, Final Office Action mailed May 12, 2008”, 8 pgs.
“U.S. Appl. No. 11/129,050, Non Final Office Action mailed Nov. 6, 2008”, 7 pgs.
“U.S. Appl. No. 11/129,050, Non Final Office Action mailed Nov. 26, 2007”, 7 pgs.
“U.S. Appl. No. 11/129,050, Notice of Allowance mailed Apr. 1, 2010”, 6 pgs.
“U.S. Appl. No. 11/129,050, Notice of Allowance mailed Jul. 16, 2010”, 4 pgs.
“U.S. Appl. No. 11/129,050, Notice of Allowance mailed Aug. 24, 2009”, 7 pgs.
“U.S. Appl. No. 11/129,050, Notice of Allowance mailed Dec. 2, 2009”, 4 pgs.
“U.S. Appl. No. 11/129,050, Response filed Feb. 23, 2009 to Non Final Office Action mailed Nov. 6, 2008”, 13 pgs.
“U.S. Appl. No. 11/129,050, Response filed Feb. 26, 2008 to Non Final Office Action mailed Nov. 26, 2007”, 14 pgs.
“U.S. Appl. No. 11/129,050, Response filed Jun. 22, 2009 to Final Office Action mailed Apr. 21, 2009”, 9 pgs.
“U.S. Appl. No. 11/129,050, Response filed Jul. 14, 2008 to Final Office Action mailed May 12, 2008”, 13 pgs.
“U.S. Appl. No. 11/129,050, Response filed Sep. 28, 2007 to Restriction Requirement mailed Aug. 1, 2007”, 11 pgs.
“U.S. Appl. No. 11/129,050, Supplemental Response filed Sep. 12, 2008 to Final Office Action mailed May 12, 2008”, 12 pgs.
“U.S. Appl. No. 11/129,058, Advisory Action mailed Oct. 17, 2007”, 3 pgs.
“U.S. Appl. No. 11/129,058, Appeal Brief filed Jan. 8, 2008”, 23 pgs.
“U.S. Appl. No. 11/129,058, Examiner's Answer to Appeal Brief mailed Jun. 18, 2008”, 14 pgs.
“U.S. Appl. No. 11/129,058, Final Office Action mailed Jul. 9, 2007”, 12 pgs.
“U.S. Appl. No. 11/129,058, Non Final Office Action mailed Jan. 29, 2007”, 11 pgs.
“U.S. Appl. No. 11/129,058, Office Communication mailed Jan. 15, 2010”, 2 pgs.
“U.S. Appl. No. 11/129,058, Response filed Apr. 30, 2007 to Non Final Office Action mailed Jan. 29, 2007”, 16 pgs.
“U.S. Appl. No. 11/129,058, Response filed Oct. 9, 2007 to Final Office Action mailed Jul. 9, 2007”, 14 pgs.
“U.S. Appl. No. 11/382,849, Final Office Action mailed Jan. 28, 2010”, 7 pgs.
“U.S. Appl. No. 11/382,849, Non-Final Office Action mailed May 12, 2010”, 5 pgs.
“U.S. Appl. No. 11/382,849, Non-Final Office Action mailed Aug. 31, 2009”, 8 pgs.
“U.S. Appl. No. 11/382,849, Response filed Apr. 26, 2010 to Final Office Action mailed Jan. 28, 2010”, 10 pgs.
“U.S. Appl. No. 11/382,849, Response filed Jun. 8, 2009 to Restriction Requirement mailed May 6, 2009”, 8 pgs.
“U.S. Appl. No. 11/382,849, Response filed Aug. 2, 2010 to Non Final Office Action mailed May 12, 2010”, 7 pgs.
“U.S. Appl. No. 11/382,849, Response filed Nov. 30, 2009 to Non Final Office Action mailed Aug. 31, 2009”, 11 pgs.
“U.S. Appl. No. 11/382,849, Restriction Requirementmailed May 6, 2009”, 6 pgs.
“U.S. Appl. No. 11/468,875, Advisory Action mailed Aug. 19, 2009”, 3 pgs.
“U.S. Appl. No. 11/468,875, Final Office Action mailed Jun. 1, 2009”, 6 pgs.
“U.S. Appl. No. 11/468,875, Non-Final Office Action mailed Dec. 11, 2008”, 8 pgs.
“U.S. Appl. No. 11/468,875, Response filed Mar. 9, 2009 to Non-Final Office Action mailed Dec. 11, 2008”, 10 pgs.
“U.S. Appl. No. 11/468,875, Response filed Aug. 3, 2009 to Final Office Action mailed Jun. 1, 2009”, 8 pgs.
“U.S. Appl. No. 11/468,875, Response filed Sep. 1, 2009 to Advisory Action mailed Aug. 19, 2009”, 9 pgs.
“U.S. Appl. No. 11/868,767, Notice of Allowance mailed Mar. 24, 2010”, 7 pgs.
“U.S. Appl. No. 11/868,767, Notice of Allowance mailed Sep. 17, 2010”, 4 pgs.
“U.S. Appl. No. 12/322,382, Advisory Action mailed Nov. 8, 2011”, 3 pgs.
“U.S. Appl. No. 12/322,382, Examiner Interview Summary mailed Jul. 22, 2014”, 2 pgs.
“U.S. Appl. No. 12/322,382, Final Office Action mailed Jan. 8, 2014”, 15 pgs.
“U.S. Appl. No. 12/322,382, Final Office Action mailed Aug. 25, 2011”, 12 pgs.
“U.S. Appl. No. 12/322,382, Non Final Office Action mailed Mar. 21, 2011”, 14 pgs.
“U.S. Appl. No. 12/322,382, Non Final Office Action mailed Aug. 26, 2013”, 14 pgs.
“U.S. Appl. No. 12/322,382, Response filed Jun. 21, 2011 to Non Final Office Action mailed Mar. 21, 2011”, 16 pgs.
“U.S. Appl. No. 12/322,382, Response filed Oct. 24, 2011 to Final Office Action mailed Aug. 25, 2011”, 15 pgs.
“U.S. Appl. No. 12/322,382, Response filed Nov. 26, 2013 to Non Final Office Action mailed Aug. 26, 2013”, 15 pgs.
“U.S. Appl. No. 12/484,727, Non Final Office Action mailed Feb. 13, 2012”, 7 pgs.
“U.S. Appl. No. 12/484,727, Non Final Office Action mailed Oct. 6, 2014”, 11 pgs.
“U.S. Appl. No. 12/484,727, Notice of Allowance mailed Jan. 15, 2015”, 5 pgs.
“U.S. Appl. No. 12/484,727, Response filed Jan. 23, 2012 to Restriction Requirement mailed Dec. 23, 2011”, 6 pgs.
“U.S. Appl. No. 12/484,727, Response filed Jun. 12, 2012 to Non Final Office Action mailed Feb. 13, 2012”, 10 pgs.
“U.S. Appl. No. 12/484,727, Response filed Dec. 16, 2014 to Non Final Office Action mailed Oct. 6, 2014”, 7 pgs.
“U.S. Appl. No. 12/484,727, Restriction Requirementmailed Dec. 23, 2011”, 7 pgs.
“U.S. Appl. No. 12/484,778, Advisory Action mailed Apr. 2, 2015”, 3 pgs.
“U.S. Appl. No. 12/484,778, Final Office Action mailed Jan. 26, 2015”, 9 pgs.
“U.S. Appl. No. 12/484,778, Non Final Office Action mailed Aug. 26, 2014”, 7 pgs.
“U.S. Appl. No. 12/484,778, Response filed Mar. 24, 2015 to Final Office Action mailed Jan. 26, 2015”, 9 pgs.
“U.S. Appl. No. 12/484,804, Final office Action mailed Jun. 5, 2012”, 10 pgs.
“U.S. Appl. No. 12/484,804, Non Final Office Action mailed Feb. 6, 2012”, 8 pgs.
“U.S. Appl. No. 12/484,804, Response filed May 3, 2012 to Non-Final Office Action mailed Feb. 6, 2012”, 12 pgs.
“U.S. Appl. No. 12/484,804, Response filed Feb. 14, 2011 to Restriction Requirement mailed Nov. 14, 2011”, 7 pgs.
“U.S. Appl. No. 12/484,804, Restriction Requirementmailed Nov. 14, 2011”, 8 pgs.
“U.S. Appl. No. 12/484,811, Non Final Office Action mailed Aug. 14, 2014”, 7 pgs.
“U.S. Appl. No. 12/694,328 , Response filed Oct. 19, 2011 to Non Final Office Action mailed Aug. 19, 2011”, 13 pgs.
“U.S. Appl. No. 12/694,328 , Response filed Nov. 21, 2011 to Advisory Action mailed Oct. 28, 2011 and Non Final Office Action mailed Aug. 19, 2011”, 13 pgs.
“U.S. Appl. No. 12/694,328, Advisory Action mailed Oct. 28, 2011”, 3 pgs.
“U.S. Appl. No. 12/694,328, Final Office Action mailed Aug. 19, 2011”, 12 pgs.
“U.S. Appl. No. 12/694,328, Final Office Action mailed Oct. 6, 2014”, 15 pgs.
“U.S. Appl. No. 12/694,328, Non Final Office Action mailed Feb. 8, 2011”, 13 pgs.
“U.S. Appl. No. 12/694,328, Non Final Office Action mailed Mar. 24, 2014”, 15 pgs.
“U.S. Appl. No. 12/694,328, Response filed Jun. 8, 2011 to Non Final Office Action mailed Feb. 8, 2011”, 12 pgs.
“U.S. Appl. No. 12/694,328, Response filed Jul. 22, 2014 to Non Final Office Action mailed Mar. 24, 2014”, 11 pgs.
“U.S. Appl. No. 13/029,631, Notice of Allowance mailed Aug. 24, 2012”, 7 pgs.
“U.S. Appl. No. 13/113,706, Non Final Office Action mailed Oct. 12, 2012”, 4 pgs.
“U.S. Appl. No. 13/113,706, Non Final Office Action Mailed Dec. 21, 2011”, 6 pgs.
“U.S. Appl. No. 13/113,706, Notice of Allowance mailed Jan. 31, 2013”, 7 pgs.
“U.S. Appl. No. 13/113,706, Response filed Jan. 9, 2013 to Non Final Office Action mailed Oct. 12, 2012”, 6 pgs.
“U.S. Appl. No. 13/113,706, Response filed Mar. 21, 2012 to Non Final Office Action mailed Dec. 21, 2011”, 14 pgs.
“U.S. Appl. No. 13/721,796, Final Office Action mailed Apr. 3, 2014”, 7 pgs.
“U.S. Appl. No. 13/721,796, Non Final Office Action mailed May 3, 2013”, 7 pgs.
“U.S. Appl. No. 13/721,796, Non Final Office Action mailed Oct. 23, 2013”, 7 pgs.
“U.S. Appl. No. 13/721,796, Notice of Allowance mailed Jun. 3, 2014”, 8 pgs.
“U.S. Appl. No. 13/721,796, Response filed Jan. 21, 2014 to Non Final Office Action mailed Oct. 23, 2013”, 10 pgs.
“U.S. Appl. No. 13/721,796, Response filed Apr. 25, 2014 to Final Office Action mailed Apr. 3, 2014”, 7 pgs.
“U.S. Appl. No. 13/838,599, Advisory Action mailed Feb. 26, 2015”, 4 pgs.
“U.S. Appl. No. 13/838,599, Final Office Action mailed Oct. 1, 2014”, 7 pgs.
“U.S. Appl. No. 13/838,599, Non Final Office Action mailed May 27, 2014”, 8 pgs.
“U.S. Appl. No. 13/838,599, Non Final Office Action mailed Aug. 31, 2015”, 5 pgs.
“U.S. Appl. No. 13/838,599, Non Final Office Action mailed Oct. 4, 2013”, 7 pgs.
“U.S. Appl. No. 13/838,599, Notice of Allowance mailed Oct. 9, 2015”, 7 pgs.
“U.S. Appl. No. 13/838,599, Response filed Aug. 12, 2014 to Non Final Office Action mailed May 27, 2014”, 9 pgs.
“U.S. Appl. No. 13/838,599, Response filed Sep. 10, 2015 to Non Final Office Action mailed Aug. 31, 2015”, 6 pgs.
“U.S. Appl. No. 13/838,599, Response filed Dec. 1, 2014 to Final Office Action mailed Oct. 1, 2014”, 9 pgs.
“U.S. Appl. No. 13/838,599, Response filed Dec. 30, 2013 to Non Final Office Action mailed Oct. 4, 2013”, 9 pgs.
“Arrow Bipolar Pacing Cathetersand Pacing Kits”, Arrow International, (2000), 4 pgs.
“Australian Application Serial No. 2007290672, First Examiner Report Received mailed Aug. 23, 2010”, 2 pgs.
“Australian Application Serial No. 2007290672, Response filed Mar. 17, 2011 to Non Final Office Action mailed Aug. 23, 2010”, 11.
“Chinese Application Serial No. 200780032286.X, Office Action mailed Feb. 13, 2012”, (English Translation), 5 pgs.
“Chinese Application Serial No. 200780032286.X, Response filed Jun. 28, 2011 to Non Final Office Action dated Feb. 23, 2011”, (w/ English Translation), 15 pgs.
“Chinese Application Serial No. 200780032286.X, Office Action mailed Feb. 23, 2011”, 5 pgs.
“Coronary Dilatation Catheters”, online]. [archived Mar. 3, 2006]. Retrieved from the Internet: <URL: http://web.archive.org/web/20060303151627/http://www.guidant.com/products/TemplatePDFs/NoPriceDilataticatheters.pdf>, (2006), 3 pgs.
“EP Search Report for EP Application No. 06824992.9 mailed Aug. 10, 2011”, 5 pgs.
“European Application Serial No. 06740227.1, Communication dated Dec. 27, 2007”, 2 pgs.
“European Application Serial No. 06740227.1, Office Action mailed Mar. 10, 2011”, 4 pgs.
“European Application Serial No. 06740227.1, Response filed Jan. 27, 2008 to Communication dated Dec. 27, 2007”, 9 pgs.
“European Application Serial No. 06740227.1, Response filed Jul. 12, 2011 to Office Action dated Mar. 10, 2011”, 15 pgs.
“European Application Serial No. 06752527.9, Communication mailed Mar. 8, 2010”, 6 pgs.
“European Application Serial No. 06752527.9, Response filed Jul. 7, 2010 to Office Action dated Mar. 8, 2010”, 15 pgs.
“European Application Serial No. 06752527.9, Summons to Attend Oral Proceedings Received mailed Jul. 23, 2010”, 3 pgs.
“European Application Serial No. 06752540.2, Communication Mar. 3, 2008”, 2 pgs.
“European Application Serial No. 06752540.2, Communication mailed Mar. 8, 2010”, 2 pgs.
“European Application Serial No. 06752540.2, Response filed Apr. 9, 2008 to Communication Mar. 3, 2008”, 6 pgs.
“European Application Serial No. 06752540.2, Response filed Jul. 15, 2010 to Communication mailed Mar. 8, 2010”, 20 pgs.
“European Application Serial No. 06762527.9, Communication pursuant to Rules 161 to 182 EPC mailed Mar. 3, 2008”, 2 pgs.
“European Application Serial No. 06762527.9, Response filed Apr. 9, 2008 to Communication pursuant to Rules 161 to 182 EPC mailed Mar. 3, 2008”, 6 pgs.
“European Application Serial No. 07797336.0, Communication mailed Mar. 10, 2010”, 3 pgs.
“European Application Serial No. 07797336.0, Office Action mailed Feb. 24, 2009”, 4 pgs.
“European Application Serial No. 07797336.0, Response filed Jul. 6, 2009 to Communication mailed Feb. 24, 2009”, 20 pgs.
“European Application Serial No. 07797336.0, Response filed Jul. 7, 2010 to Office Action dated Mar. 10, 2010”, 5 pgs.
“European Application Serial No. 07837205.9, Communication dated Apr. 8, 2009”, 2 pgs.
“European Application Serial No. 09767033.5, Office Action mailed Apr. 15, 2011”, 1 pg.
“European Application Serial No. 09767033.5, Response filed May 18, 2011 to Office Action mailed Apr. 15, 2011”, 7 pgs.
“European Application Serial No. 09767033.5, Response filed Dec. 5, 2011 to Office Action mailed Aug. 2, 2011”, 10 pgs.
“European Application Serial No. 09767043.4, Office Action mailed Apr. 14, 2011”, 1 pg.
“European Application Serial No. 09767043.4, Response filed May 24, 2011 to Office Action mailed Apr. 14, 2011”, 13 pgs.
“European Application Serial No. 09767033.5, Examination Notification Art. 94(3) mailed Aug. 2, 2011”, 6 pgs.
“Examiner's First Report on AU2011202667 mailed May 17, 2012”.
“Guidant ProductCatalog”, [online]. [archived Feb. 4, 2005]. Retrieved from the Internet: <URL: http://web.archive.org/web/20050204225345/http://guidant.com/products/VIproductcatalog.pdf>, (2005), 133 pgs.
“International Application Serial No. PCT/US/2009/003589, International Search Report mailed Sep. 14, 2009”, 5 pgs.
“International Application Serial No. PCT/US2006/018497, International Search Report mailed Oct. 24, 2006”, 5 pgs.
“International Application Serial No. PCT/US2006/018497, Written Opinion mailed Oct. 24, 2006”, 7 pgs.
“International Application Serial No. PCT/US2006/018642, International Search Report and Written Opinion mailed Oct. 24, 2006”, 14 pgs.
“International Application Serial No. PCT/US2006/018642, International Search Report mailed Oct. 24, 2006”, 5 pgs.
“International Application Serial No. PCT/US2006/018642, Written Opinion mailed Oct. 24, 2006”, 7 pgs.
“International Application Serial No. PCT/US2007/018577, International Search Report mailed Jan. 15, 2008”, 4 pgs.
“International Application Serial No. PCT/US2007/018577, Written Opinion mailed Jan. 15, 2008”, 7 pgs.
“International Application Serial No. PCT/US2007/068217, International Search Report mailed Oct. 30, 2007”, 5 pgs.
“International Application Serial No. PCT/US2007/068217, Written Opinion mailed Oct. 30, 2007”, 8 pgs.
“International Application Serial No. PCT/US2009/003575, International Search Report mailed Sep. 14, 2009”, 6 pgs.
“International Application Serial No. PCT/US2009/003575, Written Opinion mailed Sep. 14, 2009”, 9 pgs.
“International Application Serial No. PCT/US2009/003577, International Preliminary Report on Patentability mailed Jan. 6, 2011”, 12 pgs.
“International Application Serial No. PCT/US2009/003577, International Search Report mailed Aug. 9, 2009”, 5 pgs.
“International Application Serial No. PCT/US2009/003577, Written Opinion mailed Aug. 9, 2009”, 10 pgs.
“International Application Serial No. PCT/US2009/003581, International Search Report mailed Sep. 21, 2009”, 5 pgs.
“International Application Serial No. PCT/US2009/003581, Written Opinion mailed Sep. 21, 2009”, 10 pgs.
“International Application Serial No. PCT/US2009/003589, Written Opinion mailed Sep. 14, 2009”, 11 pgs.
“International Application Serial No. PCT/US2009/003590, International Preliminary Report on Patentability mailed Jan. 6, 2011”, 9 pgs.
“International Application Serial No. PCT/US2009/003590, International Search Report mailed Sep. 14, 2009”, 5 pgs.
“International Application Serial No. PCT/US2009/003590, Written Opinion mailed Sep. 14, 2009”, 10 pgs.
“International Application Serial No. PCT/US2009/003594, International Search Report mailed Sep. 17, 2009”, 5 pgs.
“International Application Serial No. PCT/US2009/003594, Written Opinion mailed Sep. 17, 2009”, 9 pgs.
“International Search Report and Written Opinion forApplication No. PCT/US2006/011972 mailed Oct. 6, 2006”, 16 pgs.
“Japanese Application Serial No. 2008-508872, Office Action mailed Oct. 27, 2011”, 6 pgs.
“Japanese Application Serial No. 2008-508872, Response filed Jan. 31, 2012 to Office Action mailed Oct. 31, 2011”, W/English Translation, 14 pgs.
“Japanese Application Serial No. 2008-511421, Office Action mailed Nov. 16, 2011”, (w/ English Translation), 5 pgs.
“Japanese Application Serial No. 2008-511421, Voluntary Amendment filed Apr. 27, 2009”, (W/ English Translation of Amended Claims), 11 pgs.
“Japanese Application Serial No. 2008-511452, OfficeAction mailed Nov. 14, 2011”, 4 pgs.
“Japanese Application Serial No. 2008-511452, Response filed Feb. 14, 2012 to Office Action mailed Nov. 14, 2011”, (English Translation of Claims), 3 pgs.
“Japanese Application Serial No. 2008-511452, Voluntary Amendment filed May 11, 2009”,(w/ English Translation of Amended Claims), 8 pgs.
“Japanese Application Serial No. 2009-510093, Voluntary Amendment filed Jan. 14, 2009”, 4 pgs.
“Japanese Application Serial No. 2011-514591, Voluntary Amendment filed Jan. 12, 2011”,(w/ English Translation), 11 pgs.
“Japanese Application Serial No. 2011-514594, Voluntary Amendment filed Jan. 18, 2011”,(w/ English Translation of Amended Claims), 49 pgs.
“Pericardial Heart Valves, Edwards Lifesciences, Cardiovascular Surgery FAQ”, [Online]. Retrieved from the Internet: <URL: http://www.edwards.com/products/cardiovascularsurgeryfaq.htm., (Accessed on Nov. 14, 2010), 1 pg.
“Product Overview: RX Acculink Carotid Stent System; RX Accunet Embolic Protection System”, [online]. [retrieved Apr. 14, 2006]. Retrieved from the Internet: <URL: http://web.archive.org/web/20060414151850/http://www.guidant com/webapp/emarketing/ppt/acculink/ACCULINK.pdf>, (2005), 23 pgs.
“RX Accunet Embolic Protection System”, [online]. [retrieved Jan. 11, 2006]. Retrieved from the Internet: <URL: http://www.guidant.com/products/ProductTemplates/ES/accunet.shtml>, (2006), 4 pgs.
“RX Accunet Embolic Protection System: Information for Prescribers”, [online]. [archived Feb. 5, 2005]. Retrieved from the Internet: <URL: http://web.archive.org/web/20050205044138/http://guidant.com/products/TemplatePDFs/ACCUNET—RX.pdf, (Jan. 6, 2005), 32 pgs.
“Southern Lights Biomaterials Homepage”, [Online]. Retrieved from the Internet: <URL:, (Accessed Jan. 7, 2011), 3 pgs.
“Supplemental Search Report from EP Application No. 048137772 mailed Aug. 19, 2011”, 2 pgs.
“Supplemental Search Report from EP Application No. 057588782 mailed Oct. 24, 2011”, 2 pgs.
“Supplemental Search Report, EP Application No. 04815634.3. mailed Aug. 19, 2011”, 2 pgs.
“Voyager RX Coronary Dilatation Catheter”, [online]. [retrieved Jan. 11, 2006]. Retrieved from the Internet: <URL: http://www.guidant.com/products/ProductTemplates/VI/RX—US—Voyager—Intro.shtml>, (2006), 2 pgs.
Airaksinen, K. E., et al., “Antiarrhythmic effectof repeated coronary occlusion during balloon angioplasty”, J Am Coll Cardiol., 29(5), (Apr. 1997), 1035-1038.
Andersen, H. R., et al., “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.”, Euro. Heart J. 13, (May 1992), 704-708.
Atwood, A., et al., “Insertion of Heart Valves by Catheterization”, The Capstone Design Course Report. MIME 1501-1502. Technical Design Report. Northeastern University., (Nov. 5, 2007), 1-93.
Atwood, A., et al., “Insertion of Heart Valves by Catheterization”, Project Supervised by Prof. S. Muftu of Northeaster University 2001-2002: 36-40, (May 2002)., (May 2002), 4 pgs.
Bodnar, E., et al., “Chapter 13—“Extinct” Cardiac Valve Prostheses”, In: Replacement Cardiac Valves, Pergamon Publishing Corporation. New York, 1991, (1991), 307-332.
Boudjemline, Y., et al., “Percutaneous implantation of a biological valve in the aorta to treat aortic valve insufficiency—a sheep study”, Med Sci. Monit. 2002; vol. 8, No. 4, (2002), BR113-BR116.
Boudjemline, Y., et al., “Percutaneous implantation of a valve in the descending aorta in lambs”, Euro. Heart J. 2002; 23, (Jul. 2002), 1045-1049.
Boudjemline, Y., et al., “Percutaneous pulmonary valve replacement in a large right ventricular outflow tract: an experimental study”, Journal of the Americal College of Cardiology; 43(6), (Mar. 2004), 1082-1087.
Boudjemline, Y., et al., “Percutaneous valve insertion: A new approach?”, J. of Thoracic and Cardio. Surg. 2003; 125(3), (Mar. 2003), 741-743.
Boudjemline, Y., et al., “Steps Toward Percutaneous Aortic Valve Replacement”, Circulation. 2002; 105, (Feb. 2002), 775-778.
Brockway, Marina V, et al., “Method and Apparatus for Delivering Chronic and Post-Ischemia Cardiac Therapies”, U.S. Appl. No. 11/207,251, filed Aug. 19, 2005, 40 pgs.
Cribier, A., et al., “Early Experience with Percutaneous Transcatheter Implantation of Heart Valve Prosthesis for the Treatment of End-Stage Inoperable Patients with Calcific Aortic Stenosis”, J. of Am. Coll. of Cardio. 2004; 43(4), (Feb. 2004), 698-703.
Cribier, A., et al., “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case”, Percutaneous Valve Technologies, Inc., TCT 2002, (Nov. 2002), 16 pgs.
Cribier, A., et al., “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description.”, Circulation. 2002; 106, (Dec. 2002), 3006-3008.
Cunliffe, H. R., et al., “Glutaraldehyde Inactivation of Exotic Animal Viruses in Swine Heart Tissue”, Applied and Environmental Microbiology; vol .37, No. 5., (May 1979), 1044-1046.
Ferrari, M., et al., “Percutaneous transvascular aortic valve replacement with self expanding stent-valve device.”, Poster from the presentation given at SMIT 2000, 12th International Conference, (Sep. 5, 2000), 1 pg.
Girouard, Steven D., “Pulmonary Vein Stent For Treating Atrial Fibrillation”, U.S. Appl. No. 60/298,741, filed Jun. 15, 2001, 14 pgs.
Haug, et al., ““Everting Heart Valve””, U.S. Appl. No. 12/492,512, filed Jun. 26, 2009.
Haug, et al., ““Methods and apparatus for endovascularly replacing a heart valve””, U.S. Appl. No. 11/716,123, filed Mar. 9, 2007.
Haug, et al., “Methods and apparatus for endovascularly replacing a patient's heart valve”, U.S. Appl. No. 12/028,452, filed Feb. 8, 2008.
Heinroth, K. M, et al., “Temporary transcoronary pacing by coated guidewires”, Clin Res Cardiol., 95, (2006), 1-6.
Henriques, Jose P., et al., “Outcome of primary angioplasty for acute myocardial infarction during routine duty hours versus during off-hours”, J Am Coll Cardiol, 41(12), (Jun. 18, 2003), 2138-2142.
Hijazi, Z. M., “Transcatheter Valve Replacement: A New Era of Percutaneous Cardiac Intervention Begins”, J. of Am. College of Cardio. 2004; 43(6), (Mar. 2004), 1088-1089.
Hourihan, Maribeth, et al., “Transcatheter Umbrella Closure of Valvular and Paravalvular Leaks”, vol. 20, No. 6, JACC, (Nov. 15, 1992), 1371-1377.
Huber, C. H., et al., “Do valved stents compromise coronary flow?”, European Journal of Cardio-thoracic Surgery. 2004; vol. 25, (May 2004), 754-759.
Kin, Hajime, et al., “Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion”, Cardiovascular Research, 62(1), (Apr. 1, 2004), 74-85.
Kis, A., “Repeated cardiac pacing extendsthe time during which canine hearts are protected against ischaemia-induced arrhythmias: role of nitric oxide.”, Journal of Molecular and Cellular Cardiology, 31(6), (Jun. 1999), 1229-1241.
Knudsen, L. L., et al., “Catheter-implanted prosthetic heart valves”, Int'l J. of Art. Organs; 1993; 16(5), (May 1993), 253-262.
Koning, M M, “Rapid ventricular pacing produces myocardial protection by nonischemic activation of KATP+ channels”, Circulation, 93(1), (Jan. 1, 1996), 178-186.
Kort, S., et al., “Minimally invasive aortic valve replacement: Echocardiographic and clinical results.”, Am. Heart J. 2001; 142(3), (Sep. 2001), 476-481.
Levy, Charles, et al., “Mycobacterium chelonei Infection of Porcine Heart Valves”, vol. 297, No. 12, The New England Journal of Medicine, (Sep. 2001), 667-668.
Love, C., et al., “The Autogenous Tissue Heart Valve: Current Status”, Journal of Cardiac Surgery. 1991; 6(4), (Dec. 1991), 499-507.
Lutter, G., et al., “Percutaneous aortic valve replacement: An experimental study. I. Studies on implantation”, J. of Thoracic and Cardio. Surg. 2002; 123(4), (Apr. 2002), 768-776.
Meier, B., et al., “Coronary Pacing During Percutaneous Transluminal Coronary Angioplasty”, Circulation, 71(3), (Mar. 1985), 557-561.
Moulopoulos, S. D., et al., “Catheter-Mounted Aortic Valves”, Annals of Thoracic Surg. 1971; 11(5), (May 1971), 423-430.
Murry, C. E., et al., “Preconditioning with ischemia:a delay of lethal cell injury in ischemic myocardium”, Circulation, 74(5), (1986), 1124-1136.
Ovize, M., et al., “Stretch preconditions canine myocardium.”, Am J Physiol., 266(1 Pt 2), (Jan. 1994), 137-46.
Paniagua, D., et al., “Heart Watch 2004”, Texas Heart Institute Spring 2004 Edition, (2004), 1-8.
Paniagua, D., et al., “Percutaneous heart valve in the chronic in vitro testing model.”, Circulation. 2002; 106, (Sep. 2002), E51-E52.
Pastore, Joseph M, et al ., “Intermittent Stress Augmentation Pacing for Cardioprotective Effect”, U.S. Appl. No. 11/458,286, filed 078-18-06, 23 pgs.
Paul, et al., ““Medical Devices and Delivery Systems for Delivering Medical Devices””, U.S. Appl. No. 12/578,447, filed Oct. 13, 2009.
Pavcnik, D., et al., “Percutaneous bioprosthetic veno valve: A long-term study in sheep.”, J. of Vascular Surg. 2002; 35(3), (Mar. 2002), 598-603.
Phillips, S. J., et al., “Phillips, S. J. et al. A Temporary Catheter-Tip Aortic Valve: Hemodynamic Effects on Experimental Acute Aortic Insufficiency”, Annals of Thoracic Surg. 1976; 21(2), (Feb. 1976), 134-136.
Rosa, A., et al., “Ectopic Pacing at Physiological Rate Improves Postanoxic Recovery of the Developing Heart”, Am. J. Physiol.—Heart Circ. Physiol., 284, (2003), 2384-2392.
Salahieh, et al., ““Repositionable heart valve and method””, U.S. Appl. No. 12/264,082, filed Nov. 3, 2008.
Salahieh, et al., ““Everting heart valve””, U.S. Appl. No. 12/269,213, filed Nov. 12, 2008.
Salahieh, et al., ““Externally expandable heart valve anchor and method””, U.S. Appl. No. 11/531,980, filed Sep. 14, 2006.
Salahieh, et al., ““Low profile heart valve and delivery system””, U.S. Appl. No. 12/132,304, filed Jun. 3, 2008.
Salahieh, et al., ““Medical Device Delivery””, U.S. Appl. No. 11/314,183, filed Dec. 20, 2005.
Salahieh, et al., ““Medical implant deployment tool””, U.S. Appl. No. 11/274,889, filed Nov. 14, 2005.
Salahieh, et al., ““Methods and apparatus for endovascularly replacing heart valve””, U.S. Appl. No. 11/532,019, filed Sep. 14, 2006.
Salahieh, et al., ““Methods and Apparatus for Performing Valvulo plasty””, U.S. Appl. No. 11/314,969, filed Dec. 20, 2005.
Salahieh, et al., ““Systems and Methods for Delivering a Medical Implant””, U.S. Appl. No. 11/706,549, filed Feb. 14, 2007.
Salahieh, et al., ““Two-Part Package for Medical Implant””, U.S. Appl. No. 11/275,913, filed Feb. 2, 2006.
Sochman, J., et al., “Percutaneous Transcatheter Aortic Disc Valve Prosthesis Implantation: A Feasibility Study”, Cardiovasc. Intervent. Radiol. 2000;23, 384-388, (Oct. 2000).
Stuart, M., “In Heart Valves, a Brave, New Non-Surgical World”, Start Up, (Feb. 2004), 9-17.
Tsang, A., et al., “Postconditioning: a form of “modified reperfusion” protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway”, Circ Res., 95(3), Epub Jul. 8, 2004, (Aug. 6, 2004), 230-2.
Vahanian, A., et al., “Percutaneous Approaches to Valvular Disease”, Circulation. 2004; 109, (Apr. 2004), 1572-1579.
Van Herwerden, L. A., et al., “Percutaneous valve implantation: back to the futures?”, Euro. Heart J. 2002; 23(18), (Sep. 2002), 1415-1416.
Vanagt, W. Y. R., et al., “Ventricular Pacing for Improving Myocardial Tolerance to Ischemia”, Progress Report on Project Guidant—CARIM, (Oct. 2003), 1-25.
Vegh, A, et al., “Transient ischaemia induced by rapid cardiac pacing results in myocardial preconditioning”, Cardiovascular Research, 25(12), (Dec. 1991), 1051-3.
Wu, Zhong-Kai, et al., “Ischemic preconditioning suppresses ventricular tachyarrhythmias after myocardial revascularization”, Circulation, 106(24), (Dec. 10, 2002), 3091-3096.
Yang, S. M., et al., “Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways”, Journal of the American College of Cardiology, 44(5), (Sep. 1, 2004), 1103-1110.
Zhao, et al., “Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning”, Am J Physiol Heart Circ Physiol, 285(2), (Aug. 2003), H579-H588.
Zhou, J. Q., et al., “Self-expandable valved stent of large size: off-bypass implantation in pulmonary position”, Eur. J. Cardiothorac. 2003; 24, (Aug. 2003), 212-216.
Related Publications (1)
Number Date Country
20160082248 A1 Mar 2016 US
Continuations (3)
Number Date Country
Parent 13838599 Mar 2013 US
Child 14925618 US
Parent 13113706 May 2011 US
Child 13838599 US
Parent 11113828 Apr 2005 US
Child 13113706 US